CardioGenics (CGNH) 10-K 13 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Oct. 31, 2013	Jan. 22, 2014
Document And Entity Information	'	'
Entity Registrant Name	'CardioGenics Holdings Inc.	'
Entity Central Index Key	'0001089029	'
Document Type	'10-K	'
Document Period End Date	31-Oct-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--10-31	'
Entity Well Known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity's Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Public Float	'	$7,871,443
Entity Common Stock Shares Outstanding	'	36,023,206
Document Fiscal Period Focus	'FY	'
Document Fiscal Year Focus	'2013	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Oct. 31, 2013	Oct. 31, 2012
Current Assets	'	'
Cash and Cash Equivalents	$263,103	$27,009
Accounts Receivable	246	437
Deposits and Prepaid Expenses	49,267	51,422
Refundable Taxes Receivable	3,302	45,207
Government Grants and Investment Tax Credits Receivable	60,104	80,080
Current Assets, Total	376,022	204,155
Long-Term Assets	'	'
Property and Equipment, net	53,496	67,827
Patents, net	118,432	110,031
Long-Term Assets, Total	171,928	177,858
Total Assets	547,950	382,013
Current Liabilities	'	'
Accounts Payable and Accrued Expenses	1,050,115	786,135
Funds Held in Trust for Redemption of Class B Common Shares	4	4
Due to Shareholders	'	100,000
Current Portion of Capital Lease Obligation	'	2,627
Notes Payable, net of debt discount	11,983	'
Derivative Liability on Notes Payable	99,702	'
Current Liabilities, Total	1,161,804	888,766
Long-Term Liabilities	'	'
Debentures Payable	303,190	'
Long-Term Liabilities, Total	303,190	'
Total Liabilities	1,464,994	888,766
Commitments and Contingencies	'	'
Deficiency	'	'
Preferred stock; par value $.0001 per share 50,000,000 shares authorized, none issued	'	'
Common stock; par value $.00001 per share; 150,000,000 shares authorized, 34,726,668 and 32,499,239 common shares and 24,176,927 and 24,176,927 exchangeable shares issued and outstanding as October 31, 2013 and 2012, respectively	565	543
Additional paid-in capital	44,514,000	42,036,498
Deficit accumulated during development stage	-44,957,870	-42,039,223
Accumulated other comprehensive loss	-117,515	-166,637
Total deficiency attributable to CardioGenics Holdings Inc.	-560,820	-168,819
Non-controlling interest	-356,224	-337,934
Total deficiency	-917,044	-506,753
Total liabilities and deficiency	$547,950	$382,013

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common Stock [Member]	'	'
Common stock, shares issued	34,726,668	32,499,239
Common stock, shares outstanding	34,726,668	32,499,239
Exchangeable Shares [Member]	'	'
Common stock, shares issued	24,176,927	24,176,927
Common stock, shares outstanding	24,176,927	24,176,927

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		191 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013
Income Statement [Abstract]	'	'	'
Revenue	'	$1,297	$10,173
Operating Expenses	'	'	'
Depreciation and Amortization of Property and Equipment	14,484	18,305	234,228
Amortization of Patent Application Costs	7,285	6,882	26,578
Write-off of Patent Application Costs	'	24,905	239,530
General and Administrative	1,886,669	741,961	10,303,700
Write-off of Goodwill	'	'	12,780,214
Research and Product Development, Net of Investment Tax Credits	419,364	522,953	4,569,697
Cost of Settlement of Lawsuit	199,000	'	1,952,800
Total operating expenses	2,526,802	1,315,006	30,106,747
Operating Loss	-2,526,802	-1,313,709	-30,096,574
Other Expenses	'	'	'
Interest Expense and Bank Charges (Net)	300,119	21,672	2,458,427
Loss on Change in Value of Derivative Liability	116,663	'	12,537,686
Loss (Gain) on Foreign Exchange Transactions	-6,647	-18,922	183,696
Total other expenses	410,135	2,750	15,179,809
Loss from Continuing Operations	-2,936,937	-1,316,459	-45,276,383
Discontinued Operations	'	'	'
Gain on Sale of Subsidiary	'	'	90,051
Loss from Discontinued Operations	'	'	-127,762
Net Loss	-2,936,937	-1,316,459	-45,314,094
Net Loss Attributed to Non-Controlling Interest	18,290	8,410	356,224
Net Loss Attributed to CardioGenics Holdings Inc.	($2,918,647)	($1,308,049)	($44,957,870)
Basic and Fully Diluted Net Loss per Common Share	($0.05)	($0.02)	'
Basic and Fully Diluted Net Loss per Common Share From Discontinued Operations	$0	$0	'
Weighted-average shares of Common Shares	57,171,924	55,629,034	'

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended																191 Months Ended
	Oct. 31, 1998	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2009	Oct. 31, 2008	Oct. 31, 2007	Oct. 31, 2006	Oct. 31, 2005	Oct. 31, 2004	Oct. 31, 2003	Oct. 31, 2002	Oct. 31, 2001	Oct. 31, 2000	Oct. 31, 1999	Oct. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Net Loss	'	($2,936,937)	($1,316,459)	'	'	'	'	'	'	'	'	'	'	'	'	'	($45,314,094)
Net Loss attributable to non-controlling interest	'	18,290	8,410	37,302	14,225	211,670	21,813	4,972	8,561	11,195	9,774	3,825	2,243	1,500	1,840	604	356,224
Net Loss attributable to CardioGenics Holdings Inc.	-81,208	-2,918,647	-1,308,049	-5,724,616	-2,024,272	-28,715,913	-1,331,408	-303,477	-522,532	-682,408	-592,706	-228,993	-156,214	-114,761	-152,525	-100,141	-44,957,870
Other comprehensive income (loss), currency translation adjustments	-2,096	49,122	6,770	64,101	82,307	-529,296	422,766	-184,432	-25,688	-13,288	-6,136	42,957	-11,506	-10,528	921	-3,489	-117,515
Comprehensive loss attributed to CordioGenics Holdings Inc.	($83,304)	($2,869,525)	($1,301,279)	($5,660,515)	($1,941,965)	($29,245,209)	($908,642)	($487,909)	($548,220)	($695,696)	($598,842)	($186,036)	($167,720)	($125,289)	($151,604)	($103,630)	($44,840,355)

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Equity (Deficiency) (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit During The Development Stage [Member]	Accumulated Other Comprehensive (Loss) [Member]	Noncontrolling Interest [Member]	Total
Balance at Nov. 19, 1997	'	'	'	'	'	'
Issuance of common shares for cash	$16	($15)	'	'	'	$1
Issuance of common shares for cash, shares	1,592,732	'	'	'	'	'
Issuance of common shares for cash, $.00	8	35,028	'	'	'	35,036
Issuance of common shares for cash, $.00, shares	796,366	'	'	'	'	'
Issuance of common shares for cash, $.00	6	24,442	'	'	'	24,448
Issuance of common shares for cash, $.00, shares	551,611	'	'	'	'	'
Issuance of common shares for cash, $.00	130	5,573	'	'	'	5,703
Issuance of common shares for cash, $.00, shares	12,986,611	'	'	'	'	'
Issuance of common shares for cash, $.01	2	17,297	'	'	'	17,299
Issuance of common shares for cash, $.01, shares	210,249	'	'	'	'	'
Issuance of common shares for cash, $.00	28	200	'	'	'	228
Issuance of common shares for cash, $.00, shares	2,787,281	'	'	'	'	'
Issuance of common shares for cash, $.01	1	6,570	'	'	'	6,571
Issuance of common shares for cash, $.01, shares	84,100	'	'	'	'	'
Issuance of common shares for cash, $.01	'	2,500	'	'	'	2,500
Issuance of common shares for cash, $.01, shares	31,949	'	'	'	'	'
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-81,208	'	'	-81,208
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-2,096	'	-2,096
Total Comprehensive Income (Loss)	'	'	-81,208	-2,096	'	-83,304
Balance at Oct. 31, 1998	191	91,595	-81,208	-2,096	'	8,482
Balance, shares at Oct. 31, 1998	19,040,899	'	'	'	'	'
Issuance of common shares for cash, $.01	'	2,500	'	'	'	2,500
Issuance of common shares for cash, $.01, shares	32,066	'	'	'	'	'
Issuance of common shares for cash, $.01	2	14,287	'	'	'	14,289
Issuance of common shares for cash, $.01, shares	159,273	'	'	'	'	'
Issuance of common shares for cash, $.01	3	24,707	'	'	'	24,710
Issuance of common shares for cash, $.01, shares	278,728	'	'	'	'	'
Commission paid on issuance of common stock for cash	'	-935	'	'	'	-935
Issuance of common shares for cash to minority shareholders, $.01	'	10,707	'	'	'	10,707
Commission paid on issuance of common stock for cash	'	-1,647	'	'	'	-1,647
Issuance of common shares for cash, $.01	'	3,814	'	'	'	3,814
Issuance of common shares for cash, $.01, shares	39,818	'	'	'	'	'
Commission paid on issuance of common stock for cash	'	-627	'	'	'	-627
Commission paid on issuance of common stock for cash	'	-314	'	'	'	-314
Issuance of common shares for cash, $.01	1	10,073	'	'	'	10,074
Issuance of common shares for cash, $.01, shares	119,455	'	'	'	'	'
Issuance of common shares for cash, $.01	1	10,045	'	'	'	10,046
Issuance of common shares for cash, $.01, shares	119,455	'	'	'	'	'
Net loss attributable to noncontrolling interest	'	'	'	'	-604	-604
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-100,141	'	'	-100,141
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-3,489	'	-3,489
Total Comprehensive Income (Loss)	'	'	-100,141	-3,489	'	-103,630
Balance at Oct. 31, 1999	198	164,205	-181,349	-5,585	-604	-23,135
Balance, shares at Oct. 31, 1999	19,789,694	'	'	'	'	'
Issuance of common shares for cash, $.03	3	99,997	'	'	'	100,000
Issuance of common shares for cash, $.03, shares	318,546	'	'	'	'	'
Issuance of common shares for minority shareholders as employee compensation, $.03	'	3,396	'	'	'	3,396
Issuance of common shares for cash, $.03	2	43,124	'	'	'	43,126
Issuance of common shares for cash, $.03, shares	167,237	'	'	'	'	'
Issuance of common shares for cash to minority shareholders, $.03	'	25,330	'	'	'	25,330
Issuance of common shares for cash, $.03	'	6,128	'	'	'	6,128
Issuance of common shares for cash, $.03, shares	23,891	'	'	'	'	'
Loan Payable plus interest exchanged for shares, $.03	4	111,996	'	'	'	112,000
Loan Payable plus interest exchanged for shares, $.03, shares	356,772	'	'	'	'	'
Issuance of stock options in exchange for services rendered	'	11,570	'	'	'	11,570
Issuance of common shares as employee compensation, $.03	'	6,611	'	'	'	6,611
Issuance of common shares in exchange for services rendered, $.14	'	11,570	'	'	'	11,570
Net loss attributable to noncontrolling interest	'	'	'	'	-1,840	-1,840
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-152,525	'	'	-152,525
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	921	'	921
Total Comprehensive Income (Loss)	'	'	-152,525	921	'	-151,604
Balance at Oct. 31, 2000	207	472,357	-333,874	-4,664	-2,444	131,582
Balance, shares at Oct. 31, 2000	20,656,140	'	'	'	'	'
Issuance of common shares for minority shareholders as employee compensation, $.03	'	6,169	'	'	'	6,169
Issuance of stock options in exchange for services rendered	'	22,269	'	'	'	22,269
Issuance of common shares as employee compensation, $.03	'	925	'	'	'	925
Issuance of common shares as employee compensation, $.03, shares	2,410	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $.14	'	22,269	'	'	'	22,269
Net loss attributable to noncontrolling interest	'	'	'	'	-1,500	-1,500
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-114,761	'	'	-114,761
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-10,528	'	-10,528
Total Comprehensive Income (Loss)	'	'	-114,761	-10,528	'	-125,289
Balance at Oct. 31, 2001	207	501,720	-448,635	-15,192	-3,944	34,156
Balance, shares at Oct. 31, 2001	20,658,550	'	'	'	'	'
Issuance of common shares for cash, $.03	11	319,011	'	'	'	319,022
Issuance of common shares for cash, $.03, shares	1,051,211	'	'	'	'	'
Issuance of common shares for minority shareholders as employee compensation, $.03	'	9,505	'	'	'	9,505
Issuance of common shares for cash, $.03	'	6,345	'	'	'	6,345
Issuance of common shares for cash, $.03, shares	20,957	'	'	'	'	'
Issuance of common shares for cash to minority shareholders, $.03	'	3,235	'	'	'	3,235
Issuance of stock options in exchange for services rendered	'	70,518	'	'	'	70,518
Issuance of common shares in exchange for services rendered, $.14	'	70,518	'	'	'	70,518
Net loss attributable to noncontrolling interest	'	'	'	'	-2,243	-2,243
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-156,214	'	'	-156,214
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-11,506	'	-11,506
Total Comprehensive Income (Loss)	'	'	-156,214	-11,506	'	-167,720
Balance at Oct. 31, 2002	218	910,334	-604,849	-26,698	-6,187	272,818
Balance, shares at Oct. 31, 2002	21,730,718	'	'	'	'	'
Issuance of common shares for cash, $.03	'	9,871	'	'	'	9,871
Issuance of common shares for cash, $.03, shares	28,292	'	'	'	'	'
Issuance of common shares for cash to minority shareholders, $.03	'	10,967	'	'	'	10,967
Issuance of stock options in exchange for services rendered	'	23,580	'	'	'	23,580
Issuance of warrants in conjunction with convertible debentures	'	358,406	'	'	'	358,406
Issuance of common shares as employee compensation, $.04	1	20,421	'	'	'	20,422
Issuance of common shares as employee compensation, $.04, shares	56,584	'	'	'	'	'
Issuance of common shares for minority shareholders as employee compensation, $.04	'	7,564	'	'	'	7,564
Issuance of common shares in exchange for services rendered, $.14	'	23,580	'	'	'	23,580
Net loss attributable to noncontrolling interest	'	'	'	'	-3,825	-3,825
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-228,993	'	'	-228,993
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	42,957	'	42,957
Total Comprehensive Income (Loss)	'	'	-228,993	42,957	'	-186,036
Balance at Oct. 31, 2003	219	1,341,143	-833,842	16,259	-10,012	513,767
Balance, shares at Oct. 31, 2003	21,815,594	'	'	'	'	'
Issuance of stock options in exchange for services rendered	'	27,669	'	'	'	27,669
Issuance of warrants in conjunction with convertible debentures	'	152,628	'	'	'	152,628
Issuance of common shares as employee compensation, $.04	1	47,316	'	'	'	47,317
Issuance of common shares as employee compensation, $.04, shares	123,646	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	2	60,147	'	'	'	60,149
Issuance of common shares as employee compensation, $.04, shares	157,177	'	'	'	'	'
Issuance of options to directors and committee chairmen for services rendered	'	54,582	'	'	'	54,582
Issuance of common shares in exchange for services rendered, $.14	'	27,669	'	'	'	27,669
Net loss attributable to noncontrolling interest	'	'	'	'	-9,774	-9,774
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-592,706	'	'	-592,706
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-6,136	'	-6,136
Total Comprehensive Income (Loss)	'	'	-592,706	-6,136	'	-598,842
Balance at Oct. 31, 2004	222	1,683,485	-1,426,548	10,123	-19,786	247,496
Balance, shares at Oct. 31, 2004	22,096,417	'	'	'	'	'
Issuance of stock options in exchange for services rendered	'	33,973	'	'	'	33,973
Issuance of common shares as employee compensation, $.04	'	3,760	'	'	'	3,760
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,692	'	'	'	3,692
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,674	'	'	'	3,674
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,629	'	'	'	3,629
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,701	'	'	'	3,701
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,641	'	'	'	3,641
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,584	'	'	'	3,584
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,628	'	'	'	3,628
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,680	'	'	'	3,680
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,737	'	'	'	3,737
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,821	'	'	'	3,821
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	'	3,822	'	'	'	3,822
Issuance of common shares as employee compensation, $.04, shares	9,431	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $.14	'	33,973	'	'	'	33,973
Net loss attributable to noncontrolling interest	'	'	'	'	-11,195	-11,195
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-682,408	'	'	-682,408
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-13,288	'	-13,288
Total Comprehensive Income (Loss)	'	'	-682,408	-13,288	'	-695,696
Balance at Oct. 31, 2005	222	1,761,827	-2,108,956	-3,165	-30,981	-381,053
Balance, shares at Oct. 31, 2005	22,209,589	'	'	'	'	'
Issuance of stock options in exchange for services rendered	'	2,658	'	'	'	2,658
Issuance of common shares as employee compensation, $.04	'	4,232	'	'	'	4,232
Issuance of common shares as employee compensation, $.04, shares	10,478	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $.04	'	4,305	'	'	'	4,305
Issuance of common shares in exchange for services rendered, $.04, shares	10,478	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $.04	'	4,321	'	'	'	4,321
Issuance of common shares in exchange for services rendered, $.04, shares	10,478	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $.14	'	2,658	'	'	'	2,658
Net loss attributable to noncontrolling interest	'	'	'	'	-8,561	-8,561
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-522,532	'	'	-522,532
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-25,688	'	-25,688
Total Comprehensive Income (Loss)	'	'	-522,532	-25,688	'	-548,220
Balance at Oct. 31, 2006	222	1,777,343	-2,631,488	-28,853	-39,542	-922,318
Balance, shares at Oct. 31, 2006	22,241,023	'	'	'	'	'
Incremental increase in fair value of warrants in conjunction with re-structuring of debentures	'	44,096	'	'	'	44,096
Net loss attributable to noncontrolling interest	'	'	'	'	-4,972	-4,972
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-303,477	'	'	-303,477
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-184,432	'	-184,432
Total Comprehensive Income (Loss)	'	'	-303,477	-184,432	'	-487,909
Balance at Oct. 31, 2007	222	1,821,439	-2,934,965	-213,285	-44,514	-1,371,103
Balance, shares at Oct. 31, 2007	22,241,023	'	'	'	'	'
Issuance of warrants in conjunction with convertible debentures	'	231,580	'	'	'	231,580
Net loss attributable to noncontrolling interest	'	'	'	'	-21,813	-21,813
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-1,331,408	'	'	-1,331,408
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	422,766	'	422,766
Total Comprehensive Income (Loss)	'	'	-1,331,408	422,766	'	-908,642
Balance at Oct. 31, 2008	222	2,053,019	-4,266,373	209,481	-66,327	-2,069,978
Balance, shares at Oct. 31, 2008	22,241,023	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	32	1,298,753	'	'	'	1,298,785
Issuance of common shares as employee compensation, $.04, shares	3,153,878	'	'	'	'	'
Issuance of common shares as employee compensation, $.04	12	503,988	'	'	'	504,000
Issuance of common shares as employee compensation, $.04, shares	1,173,592	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $.04	'	2,062	'	'	'	2,062
Issuance of common shares in exchange for services rendered, $.04, shares	5,023	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $.04	'	20,250	'	'	'	20,250
Issuance of common shares in exchange for services rendered, $.04, shares	47,153	'	'	'	'	'
Issuance of common shares as payment of debenture interest, $0.05 per share	5	236,238	'	'	'	236,243
Issuance of common shares as payment of debenture interest, $0.05 per share, shares	495,094	'	'	'	'	'
Issuance of common shares on exercise of options, shares	570,980	'	'	'	'	'
Issuance of common shares to directors, pursuant to debenture financing, $0.04 per share	9	382,521	'	'	'	382,530
Issuance of common shares to directors, pursuant to debenture financing, $0.04 per share, shares	928,394	'	'	'	'	'
Issuance of common shares for cash, $.04	'	8,602	'	'	'	8,602
Issuance of common shares for cash, $.04, shares	24,090	'	'	'	'	'
Issuance of common shares as payment of director compensation, $0.04 per share	2	103,498	'	'	'	103,500
Issuance of common shares as payment of director compensation, $0.04 per share, shares	241,005	'	'	'	'	'
Issuance of common shares to retire debentures, $0.03 per share	34	997,538	'	'	'	997,573
Issuance of common shares to retire debentures, $0.03 per share, shares	3,346,028	'	'	'	'	'
Issuance of common shares as payment of debenture interest, $0.05 per share	9	418,659	'	'	'	418,668
Issuance of common shares as payment of debenture interest, $0.05 per share, shares	855,712	'	'	'	'	'
Issuance of common shares to retire director's loan, $0.04 per share	24	884,976	'	'	'	885,000
Issuance of common shares to retire director's loan, $0.04 per share, shares	2,377,813	'	'	'	'	'
Issuance of common shares as payment of interest on director's loan, $0.04 per share	2	108,633	'	'	'	108,635
Issuance of common shares as payment of interest on director's loan, $0.04 per share, shares	218,556	'	'	'	'	'
Issuance of common shares for cash, $.04	66	2,714,934	'	'	'	2,715,000
Issuance of common shares for cash, $.04, shares	6,540,017	'	'	'	'	'
Issuance of common shares as compensation for consulting contract, $0.38 per share	1	379,999	'	'	'	380,000
Issuance of common shares as compensation for consulting contract, $0.38 per share, shares	100,000	'	'	'	'	'
Issuance of common shares on exercise of warrants by YA Global for cash	'	45,000	'	'	'	45,000
Issuance of common shares on exercise of warrants by YA Global for cash, shares	25,000	'	'	'	'	'
Beneficial conversion charge on 3rd debenture	'	335,000	'	'	'	335,000
Beneficial conversion charge on director's loan	'	117,109	'	'	'	117,109
Reclassification of warrants to derivative liability	'	-786,710	'	'	'	-786,710
Assumption of options in reverse merger	'	644,806	'	'	'	644,806
Reclassification of derivative liability on increase of authorized shares	'	13,501,360	'	'	'	13,501,360
Effect of Reverse Merger	71	11,573,465	'	'	'	11,573,536
Effect of Reverse Merger, shares	7,089,282	'	'	'	'	'
Issuance of common shares on exercise of options, $.01	6	22	'	'	'	28
Net loss attributable to noncontrolling interest	'	'	'	'	-211,670	-211,670
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-28,715,913	'	'	-28,715,913
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	-529,296	'	-529,296
Total Comprehensive Income (Loss)	'	'	-28,715,913	-529,296	'	-29,245,209
Balance at Oct. 31, 2009	495	35,543,722	-32,982,286	-319,815	-277,997	1,964,119
Balance, shares at Oct. 31, 2009	49,432,640	'	'	'	'	'
Issuance of common shares for cash	1	76,999	'	'	'	77,000
Issuance of common shares for cash, shares	77,000	'	'	'	'	'
Issuance of stock options in exchange for services rendered	'	49,000	'	'	'	49,000
Issuance of common shares in exchange for services rendered, $.14	'	49,000	'	'	'	49,000
Issuance of common shares in exchange for services rendered, $.14, shares	35,000	'	'	'	'	'
Issuance of common shares in exchange for services rendered	1	88,199	'	'	'	88,200
Issuance of common shares in exchange for services rendered, shares	78,371	'	'	'	'	'
Issuance of common shares in exchange for services rendered	'	18,000	'	'	'	18,000
Issuance of common shares in exchange for services rendered, shares	50,000	'	'	'	'	'
Common shares issued for cash	15	1,515,558	'	'	'	1,515,573
Common shares issued for cash, shares	3,031,150	'	'	'	'	'
Common shares issued for subscription receivable	1	114,999	'	'	'	115,000
Net loss attributable to noncontrolling interest	'	'	'	'	-14,225	-14,225
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-2,024,272	'	'	-2,024,272
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	82,307	'	82,307
Total Comprehensive Income (Loss)	'	'	-2,024,272	82,307	'	-1,941,965
Balance at Oct. 31, 2010	514	37,441,728	-35,006,558	-237,508	-292,222	1,905,954
Balance, shares at Oct. 31, 2010	53,009,161	'	'	'	'	'
Issuance of common shares in exchange for services rendered	5	291,495	'	'	'	291,500
Issuance of common shares in exchange for services rendered, shares	550,000	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $1.00	1	99,999	'	'	'	100,000
Issuance of common shares in exchange for services rendered, $1.00, shares	100,000	'	'	'	'	'
Issuance of common shares for cash, $.50	6	297,741	'	'	'	297,747
Issuance of common shares for cash, $.50, shares	600,000	'	'	'	'	'
Issuance of common shares for cash, $.50	1	49,999	'	'	'	50,000
Issuance of common shares for cash, $.50, shares	100,000	'	'	'	'	'
Issuance of common shares on exercise of warrants, $.47	'	10,402	'	'	'	10,402
Issuance of common shares on exercise of warrants, $.47, shares	22,005	'	'	'	'	'
Refund of common shares subscribed, $.50	'	-15,000	'	'	'	-15,000
Refund of common shares subscribed, $.50, shares	-30,000	'	'	'	'	'
Re-pricing of options in exchange for services rendered	'	163,750	'	'	'	163,750
Issuance of common shares on exercise of options, $.01	3	2,747	'	'	'	2,750
Issuance of common shares on exercise of options, $.01, shares	275,000	'	'	'	'	'
Issuance of common shares on settlement of lawsuit	10	599,990	'	'	'	600,000
Issuance of common shares on settlement of lawsuit, shares	1,000,000	'	'	'	'	'
Issuance of warrants on settlement of lawsuit	'	1,053,800	'	'	'	1,053,800
Issuance of warrants in exchange for services rendered	'	1,777,350	'	'	'	1,777,350
Net loss attributable to noncontrolling interest	'	'	'	'	-37,302	-37,302
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-5,724,616	'	'	-5,724,616
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	64,101	'	64,101
Total Comprehensive Income (Loss)	'	'	-5,724,616	64,101	'	-5,660,515
Balance at Oct. 31, 2011	540	41,774,001	40,731,174	173,407	329,524	540,436
Balance, shares at Oct. 31, 2011	55,626,166	'	'	'	'	'
Issuance of common shares for cash	3	262,497	'	'	'	'
Issuance of common shares for cash, shares	1,050,000	'	'	'	'	'
Issuance of warrants in conjunction with convertible debentures	'	'	'	'	'	'
Net loss attributable to noncontrolling interest	'	'	'	'	-8,410	-8,410
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-1,308,049	'	'	-1,308,049
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	6,770	'	6,770
Total Comprehensive Income (Loss)	'	'	-1,308,049	6,770	'	-1,301,279
Balance at Oct. 31, 2012	543	42,036,498	-42,039,223	-166,637	-337,934	-168,819
Balance, shares at Oct. 31, 2012	56,676,166	'	'	'	'	'
Issuance of warrants in conjunction with convertible debentures	'	'	'	'	'	'
Issuance of common shares in exchange for services rendered, $.04	'	'	'	'	'	1,387,025
Issuance of common shares in exchange for services rendered	4	114,021	'	'	'	114,025
Issuance of common shares in exchange for services rendered, shares	357,582	'	'	'	'	'
Issuance of common shares in exchange for services rendered	5	142,995	'	'	'	143,000
Issuance of common shares in exchange for services rendered, shares	550,000	'	'	'	'	'
Issuance of warrants in exchange for services rendered	'	1,040,000	'	'	'	1,040,000
Issuance of common shares on conversion of notes payable	3	27,216	'	'	'	27,219
Issuance of common shares on conversion of notes payable, shares	300,000	'	'	'	'	'
Issuance of common shares on conversion of notes payable	3	34,034	'	'	'	34,037
Issuance of common shares on conversion of notes payable, shares	290,649	'	'	'	'	'
Issuance of common shares on conversion of notes payable	1	13,680	'	'	'	13,681
Issuance of common shares on conversion of notes payable, shares	120,000	'	'	'	'	'
Issuance of warrants for services rendered	'	90,000	'	'	'	90,000
Issuance of common shares for cash, $0.25	4	99,996	'	'	'	100,000
Issuance of common shares for cash, $0.25, shares	400,000	'	'	'	'	'
Issuance of common shares on conversion of notes payable	2	16,943	'	'	'	16,945
Issuance of common shares on conversion of notes payable, shares	209,198	'	'	'	'	'
Value of warrants and beneficial conversion feature associated with debentures issued in the year	'	746,656	'	'	'	746,656
Settlement of derivative value of notes payable on conversion to common shares	'	151,961	'	'	'	151,961
Net loss attributable to noncontrolling interest	'	'	'	'	-18,290	-18,290
Comprehensive Income (Loss)	'	'	'	'	'	'
Net Loss	'	'	-2,918,647	'	'	-2,918,647
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Currency Translation Adjustment	'	'	'	49,122	'	49,122
Total Comprehensive Income (Loss)	'	'	-2,918,647	49,122	'	-2,869,525
Balance at Oct. 31, 2013	$565	$44,514,000	($44,957,870)	($117,515)	($356,224)	($560,820)
Balance, shares at Oct. 31, 2013	58,903,595	'	'	'	'	'

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Equity (Deficiency) (Parenthetical) (USD $)

12 Months Ended

Oct. 31, 1998

Oct. 31, 2011

Oct. 31, 2010

Oct. 31, 2009

Oct. 31, 2006

Oct. 31, 2005

Oct. 31, 2004

Oct. 31, 2003

Oct. 31, 2002

Oct. 31, 2001

Oct. 31, 2000

Oct. 31, 1999

Statement of Stockholders' Equity [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares for cash, per share

$0

$0.50

'

$0.04

'

'

'

$0.03

$0.03

'

$0.03

$0.01

Issuance of common shares for cash, per share

$0

$0.50

'

$0.04

'

'

'

'

$0.03

'

$0.03

$0.01

Issuance of common shares for cash, per share

$0

'

'

'

'

'

'

'

'

'

$0.03

$0.01

Issuance of common shares for cash, per share

$0.01

'

'

'

'

'

'

'

'

'

'

$0.01

Issuance of common shares for cash, per share

$0

'

'

'

'

'

'

'

'

'

'

$0.01

Issuance of common shares for cash, per share

$0.01

'

'

'

'

'

'

'

'

'

'

$0.01

Issuance of common shares for cash, per share

$0.01

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares for cash to minority shareholders, per share

'

'

'

'

'

'

'

$0.03

$0.03

'

$0.03

$0.01

Issuance of common shares for minority shareholders as employee compensation, per share

'

'

'

'

'

'

$0.04

$0.04

$0.03

$0.03

$0.03

'

Loan Payable plus interest exchanged for shares, per share

'

'

'

'

'

'

'

'

'

'

$0.03

'

Issuance of common shares for minority shareholders as employee compensation, per share

'

'

'

'

'

'

'

'

'

'

$0.03

'

Issuance of common shares as employee compensation, per share

'

'

'

$0.04

$0.04

$0.04

'

$0.04

'

$0.03

'

'

Issuance of common shares as directors' compensation, per share

'

'

'

$0.04

'

'

$0.04

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

$0.04

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares as employee compensation, per share

'

'

'

'

'

$0.04

'

'

'

'

'

'

Issuance of common shares in exchange for services rendered, per share

'

$1

$0.14

$0.04

$0.04

'

'

'

'

'

'

'

Issuance of common shares in exchange for services rendered, per share

'

'

'

$0.04

$0.04

'

'

'

'

'

'

'

Issuance of common shares as payment of debenture interest, per share

'

'

'

$0.05

'

'

'

'

'

'

'

'

Issuance of common shares as directors' compensation, per share

'

'

'

$0.04

'

'

'

'

'

'

'

'

ce of common shares to retire debentures, per share

'

'

'

$0.03

'

'

'

'

'

'

'

'

Issuance of common shares as payment of debenture interest, per share

'

'

'

$0.05

'

'

'

'

'

'

'

'

Issuance of common shares to retire director's loan, per share

'

'

'

$0.04

'

'

'

'

'

'

'

'

Issuance of common shares as payment of interest on director's loan, per share

'

'

'

$0.04

'

'

'

'

'

'

'

'

Issuance of common shares as compensation for consulting contract, per share

'

'

'

$0.38

'

'

'

'

'

'

'

'

Issuance of common shares on exercise of warrants, per share

'

$0.47

'

'

'

'

'

'

'

'

'

'

Refund of common shares subscribed, per share

'

$0.50

'

'

'

'

'

'

'

'

'

'

Issuance of common shares on exercise of options, per share

'

$0.01

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		191 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013
Cash flows from operating activities	'	'	'
Net Loss	($2,936,937)	($1,316,459)	($45,314,094)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation and amortization of Property and Equipment	14,484	18,305	234,228
Amortization of Patent Application Costs	7,285	6,882	26,578
Write-off of Patent Application Costs	'	24,905	239,530
Re-pricing of Options for Services Rendered	'	'	163,750
Write-off of Goodwill	'	'	12,780,214
Amortization of Deferred Debt Issuance Costs	'	'	511,035
Loss on Extinguishment of Debt	'	'	275,676
Loss on Change in Value of Derivative Liability	116,663	'	12,537,686
Interest and Discount on Notes Payable	103,862	'	13,862
Amortization of Discount on Debentures Payable	112,609	'	112,609
Interest Accrued and Foreign Exchange Loss on Debt	'	'	922,539
Unrealized Foreign Currency Exchange Gains	'	'	25,094
Beneficial Conversion Charge included in Interest Expense	'	'	452,109
Common Stock and Warrants Issued on Settlement of Lawsuit	'	'	1,653,800
Common Stock Issued as Employee or Officer/Director Compensation	'	'	2,508,282
Common Stock and Warrants Issued for Services Rendered	1,387,025	'	4,203,287
Stock Options Issued for Services Rendered	'	'	192,238
Stock Options Issued to Directors and Committee Chairman	'	'	54,582
Changes in Operating Assets and Liabilities, Net of Acquisition	'	'	'
Accounts Receivable	191	8,565	-246
Deposits and Prepaid Expenses	'	119	-50,663
Refundable Taxes Receivable	40,759	-10,016	-3,584
Government Grants and Investment Tax Credits Receivable	16,931	107,417	-43,087
Accounts Payable and Accrued Expenses	418,575	189,443	436,798
Advances	'	'	131
Net cash used in operating activities	-718,553	-970,839	-8,067,646
Cash flows from investing activities	'	'	'
Cash Acquired from Acquisition	'	'	195,885
Purchase of Property and Equipment	-153	-3,824	-223,643
Patent Application Costs	-15,686	-4,204	-334,460
Net cash used in investing activities	-15,839	-8,028	-362,218
Cash flows from financing activities	'	'	'
Due to Shareholders	'	100,000	100,000
Repayment of Capital Lease Obligation	-2,627	-25,714	-43,917
Due to Director	'	'	725,330
Issue of Notes Payable	135,000	'	135,000
Issue of Debentures	700,000	'	2,078,305
Issue of Common Shares on Exercise of Stock options	'	'	2,781
Issue of Common Shares on Exercise of Warrants	'	'	45,652
Issue of Common Shares for Cash	100,000	262,500	5,986,669
Refund of Share Subscription	'	'	-15,000
Redemption of 10% Senior Convertible Debentures	'	'	-394,972
Net cash provided by financing activities	932,373	336,786	8,619,848
Effect of foreign exchange on cash and cash equivalents	38,113	-112	73,089
Cash and Cash Equivalents	'	'	'
Increase (Decrease) in cash and cash equivalents during the period	236,094	-642,193	263,073
Beginning of Period	27,009	669,202	'
End of Period	$263,103	$27,009	$263,103

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	191 Months Ended
	Oct. 31, 2013
Statement of Cash Flows [Abstract]	'
Senior Convertible Debentures, interest rate	10.00%

Nature_of_Business

Nature of Business	12 Months Ended
	Oct. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Business	'
	1	Nature of Business
	The accompanying audited consolidated financial statements have been prepared in accordance with the requirements of Form 10-K and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) and include the results of CardioGenics, Inc. and its subsidiaries and JAG Media Holdings, Inc and its subsidiaries (“JAG Media”) (from July 31, 2009, date of acquisition) which are collectively referred to as the “Company.”
	CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products for the In-Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development. In the last quarter of 2011 CardioGenics commenced selling one of these products, but has generated no significant revenue therefrom.
	On July 31, 2009, CardioGenics acquired the business of JAG Media Holdings, Inc. (“JAG Media”). The business acquired is that of gathering and compiling financial and investment information from various financial institutions and other Wall Street professionals. Revenues of the acquired business of JAG media are generated by releasing such financial information to subscribers in a consolidated format on a timely basis through facsimile transmissions and a web site. Further, software focused on streaming video solutions was acquired through the acquisition of JAG Media by CardioGenics. Historically, further development of this software had been limited as a result of JAG Media’s lack of financial resources.
	On February 11, 2010, the Company entered into an LLC Membership Interest Purchase Agreement with Rothcove Partners LLS (“Rothcove”) pursuant to which the Company sold its interest in JAG Media to Rothcove.
	References herein to CardioGenics common shares has been retrospectively adjusted to reflect the exchange ratio of 20.957 established in the Share Purchase Agreement related to the acquisition of JAG Media.
	On October 27, 2009, the name of the Company was changed from Jag Media Holdings, Inc. to CardioGenics Holdings, Inc.
	On April 23, 2010, the Company’s Board of Directors approved a reverse stock split of its issued and outstanding common shares. The total authorized shares of common stock was at the same time reduced to 65,000,000. The Board of Directors selected a ratio of one-for-ten and the reverse stock split was effective on June 20, 2010. Trading of the Company’s common stock on the Over-The-Counter Capital Market on a split adjusted basis began at the open of trading on June 21, 2010. The reverse stock split affected all shares of the Company’s common stock, as well as options to purchase the Company’s common stock and other equity incentive awards and warrants that were outstanding immediately prior to the effective date of the reverse stock split. All references to common shares and per-share data for prior periods have been retroactively restated to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented.
	On January 17, 2013, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation to increase the authorized common shares to 150,000,000 and de-authorize the Company’s Class B common stock.

Basis_of_Presentation

Basis of Presentation	12 Months Ended
	Oct. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	2	Basis of Presentation
	The accompanying consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
	The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has a deficit accumulated at October 31, 2013 of approximately $45 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements Management’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.
	While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Oct. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3		Summary of Significant Accounting Policies
		(a)	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries. All significant intercompany transactions and balances have been eliminated.
		(b)	Development Stage Company
	The accompanying financial statements have been prepared in accordance with the provisions of the guidance for development stage enterprises.
		(c)	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
		(d)	Government Grants and Investment Tax Credits Receivable
	The Company’s accounts include claims for investment tax credits relating to scientific research activities of the Company prior to the acquisition described in Note 1. The qualification and recording of this activity for investment tax credit purposes is established by Canadian Income Tax authorities when the income tax returns for the period are assessed. The credit has been recognized in the consolidated statement of operations in the year in which the expenses were incurred.
	Subsequent to the acquisition described in Note 1, the Company no longer qualifies to receive substantial refunds of Investment Tax Credits (“ITCs”) resulting from scientific research. Currently the majority of ITCs resulting from scientific research are carried forward to a time when the company becomes tax paying at which time said ITCs are applicable against taxes payable.
		(e)	Property and Equipment
	Property under capital leases and the related obligation for future lease payments are initially recorded at an amount equal to the lesser of fair value of the property or equipment and the present value of those lease payments. Property and equipment is depreciated using methods and rates as follows:
	Furniture and Fixtures		20% declining balance
	Lab Equipment		20% declining balance
	Computer Equipment – Hardware		30% declining balance
	Computer Equipment – Software		50% declining balance
	Leasehold Improvements		Straight-line over the lesser of the life of the asset or the life of the lease
		(f)	Patents
	Capitalized patent costs represent legal and application costs incurred to establish patents. Capitalized patent costs are amortized on a straight line method over the related patent term. As patents are abandoned, the net book value of the patent is written off.
		(g)	Impairment or Disposal of Long-Lived Assets
	The Company assesses the impairment of long-lived assets under the guidance of standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable and exceeds its fair value. The carrying amount of the long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset.
		(h)	Research and Development Costs
	Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of prototype products, including payroll costs. Amounts expected to be received from governments under Scientific Research Tax Credit arrangements are offset against current expenses. The Company recognizes revenue from restricted grants in the period in which the Company has incurred the expenditures in compliance with the specific restrictions.
		(i)	Income Taxes
	The Company utilizes the liability method of accounting for income taxes as set forth in the authoritative guidance. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. As there is no certainty that the Company will generate taxable income in the foreseeable future to utilize tax losses accumulated to date, no provision for ultimate tax reduction has been made in these financial statements.
	On November 1, 2007, the Company adopted the guidance issued for accounting for uncertainty in income taxes which provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized upon the adoption of the guidance and in subsequent periods. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within operations as income tax expense. Upon adoption, there were no adjustments required.
		(j)	Stock-Based Compensation
	The Company follows the authoritative guidance for stock-based compensation which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company has also considered the related guidance of the SEC. The Company estimates the fair value of stock options and shares issued as compensation to employees and directors as of the date of grant using the Black-Scholes pricing model and restricted stock based on the per share value. The Company also follows the guidance for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants which provides guidance on transactions in which (1) the fair value of the equity instruments is more reliably measurable than the fair value of the goods or services received and (2) the counterparty receives shares of stock, stock options, or other equity instruments in settlement of the entire transaction or, if the transaction is part cash and part equity instruments, in settlement of the portion of the transaction for which the equity instruments constitute the consideration. Options issued with a nominal exercise price in exchange for services rendered were measured at the fair value of the underlying services rendered on the date of grant. The expense was recorded to the consolidated statements of operations with a corresponding increase in share capital with no additional increase in the number of shares as they were legally not yet exercised.
		(k)	Net Loss Per Common Share
	Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (loss) per share.
		(l)	Comprehensive Income (Loss)
	Other comprehensive income (loss), which includes only foreign currency translation adjustments, is shown in the consolidated statements of changes in equity (deficiency).
		(m)	Concentration of Credit Risk
	The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Canada Deposit Insurance Corporation and the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions and has not experienced any collection losses with these financial institutions.
		(n)	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. By their nature, these estimates are subject to uncertainty and the effect on the consolidated financial statements of changes in such estimates in future periods could be material.
		(o)	Foreign Currency Translation
	The Company maintains its accounting records for its Canadian operations in Canadian dollars. Transactions in United States dollars (“USD”) are translated into Canadian dollars at rates in effect at the date of the transaction and gains or losses on such transactions are recorded at the time of settlement in the consolidated statements of operations.
	The Company’s reporting currency is the United States Dollar. Foreign denominated assets and liabilities of the Company are translated into USD at the prevailing exchange rates in effect at the end of the reporting period, the historical rate for stockholders’ equity (deficiency) and a weighted average of exchange rate in effect during the period for expenses, gains and losses. Adjustments that arise from translation into the reporting currency are recorded in the accumulated other comprehensive income (loss) component of stockholders’ equity (deficiency).
		(p)	Financial Instruments
	The carrying values of cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature. Long-term debt and convertible debentures approximate their fair value based upon recent issuances of the underlying debt.
		(q)	Revenue Recognition
	Revenue included in these consolidated financial statements is derived from sales of paramagnetic beads and is recognized on shipment to customers.
		(r)	Effects of Recent Accounting Pronouncements
	In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.
	In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires an entity to provide information about the amounts reclassified out of other accumulated income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012 and interim periods within those annual periods. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2014. The Company does not expect the adoption of ASU 2013-02 to have a material effect on the consolidated financial statement presentation.
		(s)	Derivative Instruments
	The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheets as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.
		(t)	Beneficial Conversion Charge
	The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Oct. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	4	Property and Equipment
	The costs and accumulated depreciation and amortization of property and equipment are summarized as follows:
		31-Oct
		2013		2012
	Furniture and Fixtures	$	12,120	$	12,120
	Lab Equipment		168,481		168,328
	Computer Hardware		19,490		19,490
	Computer Software		8,433		8,433
	Leasehold Improvements		91,269		91,269
	Total Property and Equipment		299,793		299,640
	Less Accumulated Depreciation and Amortization		246,297		231,813
	Property and Equipment, Net	$	53,496	$	67,827
	Depreciation and amortization expense amounted to $14,484 and $18,305 for the years ended October 31, 2013 and 2012, respectively.

Patents

Patents	12 Months Ended
	Oct. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Patents	'
	5	Patents
	The costs and accumulated amortization of patents are summarized as follows:
		31-Oct
		2013			2012
	Patents	$	144,022		$	128,336
	Less: Accumulated Amortization		(25,590	)		(18,305	)
	Patents, Net	$	118,432		$	110,031
	Weighted-Average Life		17 Years			17 Years
	Amortization expense amounted to $7,285 and $6,882 for the years ended October 31, 2013 and 2012, respectively. Amortization expense is expected to be approximately $7,300 per year for the years ended October 31, 2014 through 2017. During the years ended October 31, 2013 and 2012, the Company wrote off approximately $0 and $24,905 of net book value of patents, respectively, for abandoned patents.

Due_to_Shareholders

Due to Shareholders	12 Months Ended
	Oct. 31, 2013
Related Party Transactions [Abstract]	'
Due to Shareholders	'
	6	Due to Shareholders
	The amount due to shareholders is due on demand and carries interest at 10% per annum. On February 27, 2013, the amount due to a shareholder was converted into Series A Convertible Debenture Units. (See Note 14.)

Income_Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	7	Income Taxes
	The Company adopted the provisions of the guidance for uncertainty in income taxes on November 1, 2007. The guidance clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statement, and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition classification, interest and penalties accounting in interim periods disclosure and transition.
	Based on the Company’s evaluation, management has concluded that there are no significant tax positions requiring recognition in the consolidated financial statements.
	The Company has incurred losses in Canada since inception which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of October 31, 2013 were $9,126,000 (2012 - $6,319,184) which will expire from 2014 through 2033.
	All fiscal years except 2013 have been assessed; however, claims relating to research and development credits are open for review for the fiscal years ended October 2013, 2012, 2011, 2010, 2009, 2008, 2007, and July 2009.
	As of October 31, 2013 and 2012, the Company had net operating loss carryforwards from US sources of approximately $41,040,000 and $40,713,000, respectively, available to reduce future Federal taxable income which will expire from 2020 through 2033. With certain exceptions, the Company is no longer subject to U.S. Federal income tax examinations by tax authorities for years prior to 2008.
	Internal Revenue Code Section 382 (section “382”) imposes a limitation on a corporation’s ability to utilize NOLs if it experiences an ownership change. In general, an ownership change may occur from certain transactions that increase the ownership of 5% stockholders in the stock of a corporation by more than 50 percentage points over a three year period. If an ownership change occurs, utilization of the NOLs would be subject to an annual limitation. The annual limitation under section 382 is calculated by multiplying the value of the stock at the time of the ownership change by the applicable long-term exempt rate. Any unused annual limitation may be carried over to later years. The Company has historically been in a loss position and, therefore, the Section 382 limitation may not be relevant for the current period.
	For the years ended October 31, 2013 and 2012, the Company’s effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.
	As of October 31, 2013 and 2012, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:
		31-Oct
		2013			2012
	Temporary:
	Property and equipment	$	(18,951	)	$	(14,600	)
	Net operating loss carryforwards		16,600,883			15,589,530
	Unrealized foreign exchange		17,861			16,601
	Investment tax credits		402,189			381,836
	Transitional tax debits		(25,076	)		(25,076	)
	Total Deferred Tax Assets		16,976,906			15,948,291
	Valuation Allowance		(16,976,906	)		(15,948,291	)
	Net Deferred Income Taxes	$	—		$	—
	A reconciliation of the Canadian combined statutory rate to the Company’s effective tax rate for the years ended October 31, 2013 and 2012 is as follows:
		31-Oct
		2013			2012
	Statutory rate		28	%		28	%
	Decrease in income tax rate resulting from:
	Rate differences		—			—
	Changes in tax rate		—			(1.1	)%
	Other		—			—
	Permanent differences		(5.2	)%		(18.4	)%
	Change in valuation allowance		(22.8	)%		(8.5	)%
	Effective tax rate		0	%		0	%

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Oct. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Expenses	'
	8	Accounts Payable and Accrued Expenses
		31-Oct
		2013		2012
	Accounts Payable	$	253,618	$	149,258
	Income Tax Reserve		220,000		200,000
	Research and Development		34,901		70,560
	Investor Relations		20,602		21,164
	Patent Application Costs		10,430		10,736
	Legal Fees		273,731		263,702
	Settlement of Lawsuit		199,000		—
	Accounting Fees		37,833		70,715
	Total	$	1,050,115	$	786,135

Stock_Based_Compensation

Stock Based Compensation	12 Months Ended
	Oct. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Based Compensation	'
	9	Stock-Based Compensation
	The Company follows the guidance for stock-based compensation. Stock-based employee compensation related to stock options for each of the years ended October 31, 2013 and 2012 amounted to $-0-.
	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:
						Weighted
						Average
						Exercise
			Options			Price
	Outstanding – October 31, 2011		30,000			$	0.9
	Granted			—			—
	Forfeited/expired			—			—
	Exercised			—			—
	Outstanding – October 31, 2012			30,000		$	0.9
	Granted			—			—
	Forfeited/expired			—			—
	Exercised			—			—
	Outstanding – October 31, 2013			30,000		$	0.9
	Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at October 31, 2013 and 2012.
	The fair value of each option granted is estimated on grant date using the Black-Scholes option pricing model which takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The Company granted no stock options during the years ended October 31, 2013 and 2012.
	The following table summarizes information on stock options outstanding at October 31, 2013:
	Options Outstanding and Exercisable
						Weighted
	Number		Weighted			Average
	Outstanding		Average			Remaining		Aggregate
	at		Exercise			Life		Intrinsic
	31-Oct-13		Price			(Years)		Value
	30,000		$	0.9			5.75
	30,000						5.75	$	0
			For the Year Ended October 31,
			2013			2012
	Weighted Average Fair Value of Options Granted	$	—		$	—
	Cash Received for Exercise of Stock Options	$	—		$	—
	The intrinsic value is calculated as the difference between the market value as of October 31, 2013 and the exercise price of the shares. The market value as of October 31, 2013 was $0.19 as reported by the OTC Bulletin Board.

Capital_Lease_Obligations

Capital Lease Obligations	12 Months Ended
	Oct. 31, 2013
Leases, Capital [Abstract]	'
Capital Lease Obligations	'
	10	Capital Lease Obligations
	The Company finances certain equipment acquisitions through a capital lease agreement that expired in 2013. Future minimum rental payments under capital leases and related information in years subsequent to October 31, 2013 are presented in the table below:
		31-Oct
		2013		2012
	Total amount payable in equal monthly installments of $500	$	—	$	3,000
	Less: Amount representing interest		—		373
	Present value of minimum lease payments		—		2,627
	Less: Current portion		—		2,627
		$	—	$	—

Notes_Payable

Notes Payable	12 Months Ended
	Oct. 31, 2013
Notes Payable [Abstract]	'
Notes Payable	'
	11	Notes Payable
	On November 19, 2012, the Company entered into an agreement (“Line”) with JMJ Financial (“Lender”) whereby the Company may borrow up to $350,000 from the Lender in increments of $50,000. The Line is subject to an original issue discount of $50,000. Advances under the Line (“Notes”) have a maturity date of one year from the date of the advance. If the advance is repaid within three months the advance is interest free. If not repaid within three months, the advance may not be repaid before maturity and carries interest at 5%. The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion. Unless agreed in writing by the parties, at no time will the Lender convert any amount owing under the Line into common stock that would result in the Lender owing more than 4.99% of the common stock outstanding.
	A summary of the Notes at October 31, 2013 and 2012 is as follows:
		31-Oct-13			31-Oct-12
	Convertible Note Payable, due June 27, 2014	$	25,000		$	—
	Convertible Note Payable, due September 26, 2014		35,000			—
	Debt Discount – value attributable to conversion feature attached to notes, net of accumulated amortization of $11,983		(48,017	)		—
	Total		11,983			—
	Less: Current portion		11,983			—
	Total Long-term portion	$	—		$	—
	As described in further detail in Note 12, “Derivative Liabilities”, the Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and as a derivative liability. The discount to the Notes is amortized to Loss in Change in Value of Derivative Liability over the life of the Note or until conversion. The amount charged to Loss in Change in Value of Derivative Liability for the year was $116,663. Upon conversion of the Notes and related interest and original issue discount to Common Stock, any remaining unamortized discount is charged to financing expense. During the year ended October 31, 2013, Notes in the principal amount of $75,000 plus interest and original issue discount totaling $16,882 were exchanged for 919,847 common shares.

Derivative_Liabilities

Derivative Liabilities	12 Months Ended
	Oct. 31, 2013
Derivative Liability [Abstract]	'
Derivative Liabilities	'
	12	Derivative Liabilities
	Convertible notes - embedded conversion features:
	The Notes meet the definition of a hybrid instrument, as defined in ASC 815. The hybrid instrument is comprised of a i) a debt instrument, as the host contract and ii) an option to convert the debentures into common stock of the Company, as an embedded derivative. The embedded derivatives derive their value based on the underlying fair value of the Company’s common stock. The embedded derivatives are not clearly and closely related to the underlying host debt instrument since the economic characteristics and risk associated with these derivatives are based on the common stock fair value.
	The Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and a derivative liability. The Company recognized a derivative liability of $135,000 during the year ended October 31, 2013. Accordingly, changes in the fair value of the embedded derivative are immediately recognized in earnings and classified as a gain or loss on the embedded derivative financial instrument in the accompanying consolidated statements of operations.
	The Company estimated the fair value of the embedded derivatives using a Black Scholes model with the following assumptions: conversion price $0.084 per share according to the agreements; risk free interest rate of .11%; expected life of 1 year; expected dividend of zero; a volatility factor of 170 to 195%, as of October 31, 2013. The expected lives of the instruments are equal to the contractual term of the conversion option. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option.

Fair_Value_Measurements

Fair Value Measurements

12 Months Ended

Oct. 31, 2013

Fair Value Disclosures [Abstract]

'

Fair Value Measurements

'

13

Fair Value Measurements

As defined by the Accounting Standard Codification (ASC), fair value measurements and disclosures establish a hierarchy that prioritizes fair value measurements based on the type of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of hierarchy are described below:

●

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities.

●

Level 2: Inputs other than quoted market prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets, such as interest rates and yield curves that are observable at commonly-quoted intervals.

●

Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions, as there is little, if any, related market activity.

The following table summarizes the financial liabilities measured at fair value on a recurring basis as of October 31, 2013, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:

Quoted Prices in

Total Increase (Reduction)

Active Markets for

Significant Other

Significant

in Fair Value

Balance Sheet

Identical Assets or

Observable Inputs

Unobservable

31-Oct-13

Recorded at

Location

Liabilities (Level 1)

(Level 2)

Inputs (Level 3)

Total

31-Oct-13

Liabilities:

Derivative liability on Notes Payable

$

-

$

-

$

99,702

$

99,702

$

-

The Company utilizes the Black-Scholes Option Pricing model to estimate the fair value of the derivative liability associated with the convertible note obligation. The Company considers them to be Level 3 instruments. The following table shows the weighted average assumptions the Company used to develop the fair value estimates for the determination of the derivative liability at October 31, 2013:

Fair value

$0.139-.140

Expected volatility

170-197%

Dividend yield

—

Expected term (in years)

.66-.90

Risk-free interest rate

0.11

%

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the year ended October 31, 2013.

Balance at beginning of period

$

—

Additions to derivative instruments

135,000

Change in fair value of derivative liabilities

116,663

Settlements

(151,961

)

Balance at end of period

$

99,702

Debentures_Payable

Debentures Payable	12 Months Ended
	Oct. 31, 2013
Debt Disclosure [Abstract]	'
Debentures Payable	'
	14	Debentures Payable
	In February 2013, a shareholder loan in the amount of $100,000 was converted on a dollar-for-dollar basis for Series A Convertible Debenture Units (the “A Units”). Each A Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.25 per share at any time up to three years.
	In February 2013, loans from shareholder/directors in the amount of $188,584 were converted on a dollar-for-dollar basis for Series A Convertible Debenture Units (the “A Units”). Each A Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.25 per share at any time up to three years.
	In May 2013 the Company sold Series B Convertible Debenture Units (the “B Units”) in the amount of $500,000. Each B Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years.
	In June 2013 the Company sold Series B Convertible Debenture Units (the “B Units”) in the amount of $148,653 to officers and/or directors. Each B Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years.
	The Company allocated proceeds of $306,900 to the fair value of the warrants using a Black Scholes model with the following assumptions: conversion price $0.25 or $0.15 per share according to the agreements; risk free interest rate of .18%; expected life of 3 years; expected dividend of zero; a volatility factor of 176 to 195%, as of October 31, 2013 and the remaining $343,996 to the fair value of the Series B Convertible Debentures. Based on the excess of the aggregate fair value of the common shares that would have been issued if the Series B Convertible Debentures had been converted immediately over the proceeds allocated to the Series B Convertible Debentures, the investors received a beneficial conversion feature that had an aggregate intrinsic value of $343,996 as of the commitment date. Accordingly, the Company recorded an increase in additional paid-in capital and debt discount of $650,896 in connection with the issuance of the Series B Convertible Debentures and warrants.
	A summary of the Debentures at October 31, 2013 and 2012 is as follows:
		31-Oct-13			31-Oct-12
	Series A Convertible Debentures Payable, interest at 10% per annum to maturity at February 27, 2016	$	288,584		$	—
	Series B Convertible Debentures Payable, interest at 10% per annum to maturity at May 31, 2016		500,000			—
	Series B Convertible Debentures Payable, interest at 10% per annum to maturity at June 3, 2016		148,653			—
	Debt Discount		(634,047	)		—
	Total		303,190			—
	Less: Current portion		—			—
	Total Long-term portion	$	303,190		$	—
	Debt discount is amortized to Interest Expense over the life of the Debentures. The amount amortized to Interest Expense for the year ended October 31, 2013 was $112,609.

Deficiency

Deficiency	12 Months Ended
	Oct. 31, 2013
Stockholders' Equity Note [Abstract]	'
Deficiency	'
	15	Deficiency
	Equity Instruments Issued for Services Rendered
	During the years ended October 31, 2000 through 2006, CardioGenics Inc. issued stock options with a nominal exercise price in exchange for services rendered to CardioGenics Inc. The fair value of each stock option was measured at the fair value of the underlying services on the date of grant. The fair value of each grant was charged to the related expense in the consolidated statements of operations.
	The Company assumed options outstanding at JAG Media entitling the employees to purchase 75,000 common shares of the Company’s stock at a price of $0.20 per share to August 31, 2011. The Company issued options to employees entitling the employees to purchase 200,000 common shares of the Company’s stock at a price of $3.40 per share to July 31, 2019, based upon change of control provisions in their employment agreements. All these options were immediately vested. The fair value of the 275,000 options was included in the purchase price. During 2011, these options were re-priced at $0.01 per share and subsequently exercised.
	On August 1, 2009, the Company issued options to a consultant entitling the consultant to purchase 30,000 common shares of the Company’s stock at a price of $0.90 per share to July 31, 2019. These options were immediately vested.
		October 31,
		2013		2012
	Warrants
	Outstanding warrants are as follows:
	Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of $0.90 per common share up to and including July 31, 2017		—		287,085
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016		250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016		250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016		500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
	Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including March 20, 2013		—		1,500,000
	Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.34 per common share up to and including March 20, 2013		—		1,500,000
	Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including March 20, 2013		—		1,000,000
	Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016		600,000		—
	Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		750,000		—
	Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		232,500		—
	Issued to consultants August 5, 2013, entitling the holders to purchase 2,500,000 common shares in the company at an exercise price of $0.15 per common share up to and including August 4, 2023		2,500,000		—
	Issued to consultants August 5, 2013, entitling the holders to purchase 1,500,000 common shares in the company at an exercise price of $0.10 per common share up to and including August 4, 2023		1,500,000		—
	Issued to consultant September 3, 2013, entitling the holder to purchase 500,000 common shares in the company at an exercise price of $0.50 per common share up to and including July 31, 2018		500,000		—
	Issued to shareholder October 29, 2013, entitling the holder to purchase 250,000 common shares in the company at an exercise price of $0.15 per common share up to and including October 29, 2016		250,000		—
	Total Warrants outstanding		8,332,500		6,287,085

Authorized_Share_Capital

Authorized Share Capital	12 Months Ended
	Oct. 31, 2013
Partners' Capital Notes [Abstract]	'
Authorized Share Capital	'
	16	Authorized Share Capital
	On September 30, 2009, the Company’s articles of incorporation were amended to increase the total number of common shares authorized for issuance from 500,000,000 shares to 650,000,000 shares of common stock, par value $0.00001 per share. On April 23, 2010, the Company’s Board of Directors approved a reverse stock split of its issued and outstanding common shares. The total authorized shares was at the same time reduced to 65,000,000. The Board of Directors selected a ratio of one-for-ten and the reverse split was effective June 20, 2010. As a result, the total number of shares of all classes of capital stock authorized for issuance by the Company decreased from 700,440,000 shares to 70,044,000 shares with a par value of $.00001 per share, of which 5,000,000 shares are authorized for issuance as preferred stock, 65,000,000 shares are authorized for issuance as common stock, 40,000 shares are authorized for issuance as Series 2 Class B common stock and 4,000 shares are authorized for issuance as Series 3 Class B common stock. On January 17, 2013 the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation to increase the authorized common shares to 150,000,000 and de-authorize the Company’s Class B common stock.

Issuance_of_Common_Stock

Issuance of Common Stock	12 Months Ended
	Oct. 31, 2013
Issuance Of Common Stock	'
Issuance of Common Stock	'
	17	Issuance of Common Stock
	During the year ended October 31, 2013 and 2012 the Company issued the following common shares:
		Year Ended October 31, 2013				Year Ended October 31, 2012
		# of shares		Amount		# of shares		Amount
	Issuance to third parties for services rendered		907,582	$	257,025		—	$	—
	Issuance to third parties for cash		400,000	$	100,000		1,050,000	$	262,500
	Issuance to third parties on exercise of conversion of notes payable		919,847	$	91,882		—	$	—
	The fair value of shares issued for services rendered were measured at the fair value of the services rendered on the date rendered.

Redemption_of_Class_B_Common_S

Redemption of Class B Common Stock	12 Months Ended
	Oct. 31, 2013
Redemption Of Class B Common Stock	'
Redemption Of Class B Common Stock	'
	18	Redemption of Class B Common Stock
	On or about February 28, 2011 CardioGenics Holdings Inc. (“Holdings”) mailed notices to the holders of its outstanding Series 2 Class B Common Stock (the “Series 2 Shares”) and Series 3 Class B Common Stock (the “Series 3 Shares”), which notify such stockholders that Holdings has elected to redeem all outstanding Series 2 Shares and Series 3 Shares in accordance with their terms. The Redemption Date is April 4, 2011 and the Redemption Price is par value, $0.00001 per share.
	Holdings has established a trust account with TD Bank Canada, which account will hold proceeds sufficient to redeem the issued and outstanding Series 2 Shares and Series 3 Shares. Accordingly, notwithstanding that any certificate for Series 2 Shares or Series 3 Shares called for redemption shall not have been surrendered for cancellation, all Series 2 Shares and Series 3 Shares called for redemption shall no longer be deemed outstanding, and all rights with respect to such Series 2 Shares and Series 3 Shares shall forthwith on the Redemption Date cease and terminate, except only the right of the holders thereof to receive the pro-rata amount payable of the Series 2 Shares and Series 3 Shares, without interest.

Equity_Line

Equity Line	12 Months Ended
	Oct. 31, 2013
Equity Line	'
Equity Line	'
	19	Equity Line
	On September 27, 2013, CardioGenics Holdings Inc. (the “Company”) entered into an investment agreement (the “Investment Agreement”) with Dutchess Opportunity Fund, II, LP (the “Investor”), whereby the Company may sell, and the Investor is obligated to purchase, up to $5 million (the “Put Offering”) of the Company’s common, par value $0.00001 per share (the “Common Stock”). The purchase price of any shares of Common Stock sold pursuant to the Put Offering shall be determined by the lowest daily volume weighted average price during the applicable pricing period. Any shares of Common Stock sold in the Put Offering will be sold pursuant to a registration statement to be filed by the Company pursuant to the terms of a registration rights agreement (as defined below). Any shares of Common Stock sold pursuant to the Put Offering will be sold directly to the Investor without a placement agent, underwriter, broker or dealer.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Oct. 31, 2013
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	20	Net Loss per Share
	The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share:
		Years Ended October 31,
		2013		2012
	Weighted-average shares - basic		57,171,924		55,629,034
	Effect of dilutive securities		—		—
	Weighted-average shares - diluted		57,171,924		55,629,034
	Basic earnings per share (“EPS”) and diluted EPS for the years ended October 31, 2013 and 2012 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants and conversion of debt representing 12,896,786 and 6,317,085 incremental shares, respectively, have been excluded from the years ended October 31, 2013 and 2012, respectively, computation of diluted EPS as they are antidilutive given the net losses generated.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Oct. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	21	Commitments and Contingent Liabilities
	Lease
	The Company has entered into an operating lease agreement for the use of operating space.
	Aggregate minimum annual lease commitments of the Company under the non-cancelable operating lease as of October 31, 2013 are as follows. (The Company is required in addition to pay a proportionate share of building operational expenses.) :
	Year	Amount
	2014	$	49,639
	2015		49,891
	2016		51,152
	Thereafter		42,627
	Total Minimum Lease Payments	$	193,309
	Lease expense amounted to $60,513 and $76,602 for the years ended October 31, 2013 and 2012, respectively.
	The preceding data reflects existing leases and does not include replacements upon their expiration. In the normal course of business, operating leases are generally renewed or replaced by other leases.
	Lawsuit
	On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of $514,000. The suit was settled subsequent to October 31, 2013 (see Note 23).

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	12 Months Ended
	Oct. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Disclosure of Cash Flow Information	'
	22	Supplemental Disclosure of Cash Flow Information
		For the Year Ended
		October 31,
		2013		2012
	Cash paid during the period for:
	Interest	$	28,116	$	18,221
	Income Taxes		—		—
	Non-cash financing activities:
	Conversion of shareholder loan and accrued expenses to debentures		255,000		—
	Conversion of notes payable including principle, interest and original issue discount		91,882		—
	Value of beneficial conversion feature and warrants issued with debentures issued		746,656		—
	during the year

Subsequent_Events

Subsequent Events	12 Months Ended
	Oct. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	23		Subsequent Events
		a)	Issuance of Common Shares
	On November 15, 2013, the Company issued 200,000 common shares at a price of $0.25 per share for cash consideration of $50,000. The investor also received warrants entitling the shareholder to purchase 125,000 common shares at a price of $0.15 per share for a term of three (3) years.
		b)	Settlement of Lawsuit
	On January 3, 2014, the Company settled a suit from a former employee who claimed compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company for an amount equal to $10,000 plus 700,000 common shares. At October 31, 2013 the Company accrued a Settlement of Lawsuit expense in the amount of $199,000.
		c)	Non-controlling Interest
	On January 3, 2014, shareholders of Cardiogenics Inc. that had at July 31, 2009 opted not to exchange their shares in Cardiogenics Inc. for shares in Cardiogenics Holdings Inc. elected to exchange their shares in Cardiogenics Inc. for 296,538 common shares of Cardiogenics Holdings Inc. which is the same number of shares to which they would have been entitled had they exercised their option July 31, 2009.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation	'
		(a)	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries. All significant intercompany transactions and balances have been eliminated.
Development Stage Company	'
		(b)	Development Stage Company
	The accompanying financial statements have been prepared in accordance with the provisions of the guidance for development stage enterprises.
Cash and Cash Equivalents	'
		(c)	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Government Grants and Investment Tax Credits Receivable	'
		(d)	Government Grants and Investment Tax Credits Receivable
	The Company’s accounts include claims for investment tax credits relating to scientific research activities of the Company prior to the acquisition described in Note 1. The qualification and recording of this activity for investment tax credit purposes is established by Canadian Income Tax authorities when the income tax returns for the period are assessed. The credit has been recognized in the consolidated statement of operations in the year in which the expenses were incurred.
	Subsequent to the acquisition described in Note 1, the Company no longer qualifies to receive substantial refunds of Investment Tax Credits (“ITCs”) resulting from scientific research. Currently the majority of ITCs resulting from scientific research are carried forward to a time when the company becomes tax paying at which time said ITCs are applicable against taxes payable.
Property and Equipment	'
		(e)	Property and Equipment
	Property under capital leases and the related obligation for future lease payments are initially recorded at an amount equal to the lesser of fair value of the property or equipment and the present value of those lease payments. Property and equipment is depreciated using methods and rates as follows:
	Furniture and Fixtures		20% declining balance
	Lab Equipment		20% declining balance
	Computer Equipment – Hardware		30% declining balance
	Computer Equipment – Software		50% declining balance
	Leasehold Improvements		Straight-line over the lesser of the life of the asset or the life of the lease
Patents	'
		(f)	Patents
	Capitalized patent costs represent legal and application costs incurred to establish patents. Capitalized patent costs are amortized on a straight line method over the related patent term. As patents are abandoned, the net book value of the patent is written off.
Impairment or Disposal of Long-Lived Assets	'
		(g)	Impairment or Disposal of Long-Lived Assets
	The Company assesses the impairment of long-lived assets under the guidance of standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable and exceeds its fair value. The carrying amount of the long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset.
Research and Development Costs	'
		(h)	Research and Development Costs
	Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of prototype products, including payroll costs. Amounts expected to be received from governments under Scientific Research Tax Credit arrangements are offset against current expenses. The Company recognizes revenue from restricted grants in the period in which the Company has incurred the expenditures in compliance with the specific restrictions.
Income Taxes	'
		(i)	Income Taxes
	The Company utilizes the liability method of accounting for income taxes as set forth in the authoritative guidance. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. As there is no certainty that the Company will generate taxable income in the foreseeable future to utilize tax losses accumulated to date, no provision for ultimate tax reduction has been made in these financial statements.
	On November 1, 2007, the Company adopted the guidance issued for accounting for uncertainty in income taxes which provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized upon the adoption of the guidance and in subsequent periods. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within operations as income tax expense. Upon adoption, there were no adjustments required.
Stock-Based Compensation	'
		(j)	Stock-Based Compensation
	The Company follows the authoritative guidance for stock-based compensation which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company has also considered the related guidance of the SEC. The Company estimates the fair value of stock options and shares issued as compensation to employees and directors as of the date of grant using the Black-Scholes pricing model and restricted stock based on the per share value. The Company also follows the guidance for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants which provides guidance on transactions in which (1) the fair value of the equity instruments is more reliably measurable than the fair value of the goods or services received and (2) the counterparty receives shares of stock, stock options, or other equity instruments in settlement of the entire transaction or, if the transaction is part cash and part equity instruments, in settlement of the portion of the transaction for which the equity instruments constitute the consideration. Options issued with a nominal exercise price in exchange for services rendered were measured at the fair value of the underlying services rendered on the date of grant. The expense was recorded to the consolidated statements of operations with a corresponding increase in share capital with no additional increase in the number of shares as they were legally not yet exercised.
Net Loss Per Common Share	'
		(k)	Net Loss Per Common Share
	Basic loss per share is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (loss) per share.
Comprehensive Income (Loss)	'
		(l)	Comprehensive Income (Loss)
	Other comprehensive income (loss), which includes only foreign currency translation adjustments, is shown in the consolidated statements of changes in equity (deficiency).
Concentration of Credit Risk	'
		(m)	Concentration of Credit Risk
	The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Canada Deposit Insurance Corporation and the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions and has not experienced any collection losses with these financial institutions.
Use of Estimates	'
		(n)	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. By their nature, these estimates are subject to uncertainty and the effect on the consolidated financial statements of changes in such estimates in future periods could be material.
Foreign Currency Translation	'
		(o)	Foreign Currency Translation
	The Company maintains its accounting records for its Canadian operations in Canadian dollars. Transactions in United States dollars (“USD”) are translated into Canadian dollars at rates in effect at the date of the transaction and gains or losses on such transactions are recorded at the time of settlement in the consolidated statements of operations.
	The Company’s reporting currency is the United States Dollar. Foreign denominated assets and liabilities of the Company are translated into USD at the prevailing exchange rates in effect at the end of the reporting period, the historical rate for stockholders’ equity (deficiency) and a weighted average of exchange rate in effect during the period for expenses, gains and losses. Adjustments that arise from translation into the reporting currency are recorded in the accumulated other comprehensive income (loss) component of stockholders’ equity (deficiency).
Financial Instruments	'
		(p)	Financial Instruments
	The carrying values of cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature. Long-term debt and convertible debentures approximate their fair value based upon recent issuances of the underlying debt.
Revenue Recognition	'
		(q)	Revenue Recognition
	Revenue included in these consolidated financial statements is derived from sales of paramagnetic beads and is recognized on shipment to customers.
Effects of Recent Accounting Pronouncements	'
		(r)	Effects of Recent Accounting Pronouncements
	In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.
	In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires an entity to provide information about the amounts reclassified out of other accumulated income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012 and interim periods within those annual periods. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2014. The Company does not expect the adoption of ASU 2013-02 to have a material effect on the consolidated financial statement presentation.
Derivative Instruments	'
		(s)	Derivative Instruments
	The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheets as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.
Beneficial Conversion Charge	'
		(t)	Beneficial Conversion Charge
	The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Oct. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Property Plant and Equipment Depreciated Methods and Rates	'
	Property and equipment is depreciated using methods and rates as follows:
	Furniture and Fixtures	20% declining balance
	Lab Equipment	20% declining balance
	Computer Equipment – Hardware	30% declining balance
	Computer Equipment – Software	50% declining balance
	Leasehold Improvements	Straight-line over the lesser of the life of the asset or the life of the lease

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Oct. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of Cost and Accumulated Depreciation and Amortization of Property Plant and Equipment	'
	The costs and accumulated depreciation and amortization of property and equipment are summarized as follows:
		31-Oct
		2013		2012
	Furniture and Fixtures	$	12,120	$	12,120
	Lab Equipment		168,481		168,328
	Computer Hardware		19,490		19,490
	Computer Software		8,433		8,433
	Leasehold Improvements		91,269		91,269
	Total Property and Equipment		299,793		299,640
	Less Accumulated Depreciation and Amortization		246,297		231,813
	Property and Equipment, Net	$	53,496	$	67,827

Patents_Tables

Patents (Tables)	12 Months Ended
	Oct. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Costs and Accumulated Amortization of Patents	'
	The costs and accumulated amortization of patents are summarized as follows:
		31-Oct
		2013			2012
	Patents	$	144,022		$	128,336
	Less: Accumulated Amortization		(25,590	)		(18,305	)
	Patents, Net	$	118,432		$	110,031
	Weighted-Average Life		17 Years			17 Years

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2013
Income Tax Disclosure [Abstract]	'
Deferred Tax Assets Consisted of the Effects of Temporary Differences	'
	As of October 31, 2013 and 2012, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:
		31-Oct
		2013			2012
	Temporary:
	Property and equipment	$	(18,951	)	$	(14,600	)
	Net operating loss carryforwards		16,600,883			15,589,530
	Unrealized foreign exchange		17,861			16,601
	Investment tax credits		402,189			381,836
	Transitional tax debits		(25,076	)		(25,076	)
	Total Deferred Tax Assets		16,976,906			15,948,291
	Valuation Allowance		(16,976,906	)		(15,948,291	)
	Net Deferred Income Taxes	$	—		$	—
Canadian Combined Statutory Rate to the Company's Effective Tax Rate	'
	A reconciliation of the Canadian combined statutory rate to the Company’s effective tax rate for the years ended October 31, 2013 and 2012 is as follows:
		31-Oct
		2013			2012
	Statutory rate		28	%		28	%
	Decrease in income tax rate resulting from:
	Rate differences		—			—
	Changes in tax rate		—			(1.1	)%
	Other		—			—
	Permanent differences		(5.2	)%		(18.4	)%
	Change in valuation allowance		(22.8	)%		(8.5	)%
	Effective tax rate		0	%		0	%

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Oct. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities	'
	8	Accounts Payable and Accrued Expenses
		31-Oct
		2013		2012
	Accounts Payable	$	253,618	$	149,258
	Income Tax Reserve		220,000		200,000
	Research and Development		34,901		70,560
	Investor Relations		20,602		21,164
	Patent Application Costs		10,430		10,736
	Legal Fees		273,731		263,702
	Settlement of Lawsuit		199,000		—
	Accounting Fees		37,833		70,715
	Total	$	1,050,115	$	786,135

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Oct. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity	'
	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:
						Weighted
						Average
						Exercise
			Options			Price
	Outstanding – October 31, 2011		30,000			$	0.9
	Granted			—			—
	Forfeited/expired			—			—
	Exercised			—			—
	Outstanding – October 31, 2012			30,000		$	0.9
	Granted			—			—
	Forfeited/expired			—			—
	Exercised			—			—
	Outstanding – October 31, 2013			30,000		$	0.9
Summarizes Information on Stock Options Outstanding	'
	The following table summarizes information on stock options outstanding at October 31, 2013:
	Options Outstanding and Exercisable
						Weighted
	Number		Weighted			Average
	Outstanding		Average			Remaining		Aggregate
	at		Exercise			Life		Intrinsic
	31-Oct-13		Price			(Years)		Value
	30,000		$	0.9			5.75
	30,000						5.75	$	0
Fair Value and Received From Exercise Of Stock Option	'
			For the Year Ended October 31,
			2013			2012
	Weighted Average Fair Value of Options Granted	$	—		$	—
	Cash Received for Exercise of Stock Options	$	—		$	—

Capital_Lease_Obligations_Tabl

Capital Lease Obligations (Tables)	12 Months Ended
	Oct. 31, 2013
Leases, Capital [Abstract]	'
Future Minimum Rental Payments Under Capital leases	'
	The Company finances certain equipment acquisitions through a capital lease agreement that expired in 2013. Future minimum rental payments under capital leases and related information in years subsequent to October 31, 2013 are presented in the table below:
		31-Oct
		2013		2012
	Total amount payable in equal monthly installments of $500	$	—	$	3,000
	Less: Amount representing interest		—		373
	Present value of minimum lease payments		—		2,627
	Less: Current portion		—		2,627
		$	—	$	—

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Oct. 31, 2013
Notes Payable [Abstract]	'
Summary of Notes Payable	'
	A summary of the Notes at October 31, 2013 and 2012 is as follows:
		31-Oct-13			31-Oct-12
	Convertible Note Payable, due June 27, 2014	$	25,000		$	—
	Convertible Note Payable, due September 26, 2014		35,000			—
	Debt Discount – value attributable to conversion feature attached to notes, net of accumulated amortization of $11,983		(48,017	)		—
	Total		11,983			—
	Less: Current portion		11,983			—
	Total Long-term portion	$	—		$	—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)

12 Months Ended

Oct. 31, 2013

Fair Value Disclosures [Abstract]

'

Schedule of Fair Value of Liabilities Measured on Recurring Basis

'

The following table summarizes the financial liabilities measured at fair value on a recurring basis as of October 31, 2013, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:

Quoted Prices in

Total Increase (Reduction)

Active Markets for

Significant Other

Significant

in Fair Value

Balance Sheet

Identical Assets or

Observable Inputs

Unobservable

31-Oct-13

Recorded at

Location

Liabilities (Level 1)

(Level 2)

Inputs (Level 3)

Total

31-Oct-13

Liabilities:

Derivative liability on Notes Payable

$

-

$

-

$

99,702

$

99,702

$

-

Schedule of Fair Value of Estimated Derivative Liabilities Weighted Average Assumption

'

The following table shows the weighted average assumptions the Company used to develop the fair value estimates for the determination of the derivative liability at October 31, 2013:

Fair value

$0.139-.140

Expected volatility

170-197%

Dividend yield

—

Expected term (in years)

.66-.90

Risk-free interest rate

0.11

%

Schedule of Changes In Fair Value of Financial Liabilities or Derivative Liabilities

'

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the year ended October 31, 2013.

Balance at beginning of period

$

—

Additions to derivative instruments

135,000

Change in fair value of derivative liabilities

116,663

Settlements

(151,961

)

Balance at end of period

$

99,702

Debentures_Payable_Tables

Debentures Payable (Tables)	12 Months Ended
	Oct. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Debenture Payable	'
	A summary of the Debentures at October 31, 2013 and 2012 is as follows:
		31-Oct-13			31-Oct-12
	Series A Convertible Debentures Payable, interest at 10% per annum to maturity at February 27, 2016	$	288,584		$	—
	Series B Convertible Debentures Payable, interest at 10% per annum to maturity at May 31, 2016		500,000			—
	Series B Convertible Debentures Payable, interest at 10% per annum to maturity at June 3, 2016		148,653			—
	Debt Discount		(634,047	)		—
	Total		303,190			—
	Less: Current portion		—			—
	Total Long-term portion	$	303,190		$	—

Deficiency_Tables

Deficiency (Tables)	12 Months Ended
	Oct. 31, 2013
Stockholders' Equity Note [Abstract]	'
Shedule of Warrants Outstanding	'
	On August 1, 2009, the Company issued options to a consultant entitling the consultant to purchase 30,000 common shares of the Company’s stock at a price of $0.90 per share to July 31, 2019. These options were immediately vested.
		October 31,
		2013		2012
	Warrants
	Outstanding warrants are as follows:
	Issued to consultant August 1, 2009, entitling the holder to purchase 1 common share in the company at an exercise price of $0.90 per common share up to and including July 31, 2017		—		287,085
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016		250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016		250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016		500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
	Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including March 20, 2013		—		1,500,000
	Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.34 per common share up to and including March 20, 2013		—		1,500,000
	Issued to consultants in September 2011 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including March 20, 2013		—		1,000,000
	Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016		600,000		—
	Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		750,000		—
	Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		232,500		—
	Issued to consultants August 5, 2013, entitling the holders to purchase 2,500,000 common shares in the company at an exercise price of $0.15 per common share up to and including August 4, 2023		2,500,000		—
	Issued to consultants August 5, 2013, entitling the holders to purchase 1,500,000 common shares in the company at an exercise price of $0.10 per common share up to and including August 4, 2023		1,500,000		—
	Issued to consultant September 3, 2013, entitling the holder to purchase 500,000 common shares in the company at an exercise price of $0.50 per common share up to and including July 31, 2018		500,000		—
	Issued to shareholder October 29, 2013, entitling the holder to purchase 250,000 common shares in the company at an exercise price of $0.15 per common share up to and including October 29, 2016		250,000		—
	Total Warrants outstanding		8,332,500		6,287,085

Issuance_of_Common_Stock_Table

Issuance of Common Stock (Tables)	12 Months Ended
	Oct. 31, 2013
Issuance Of Common Stock Tables	'
Schedule of Common Stock Issue	'
	During the year ended October 31, 2013 and 2012 the Company issued the following common shares:
		Year Ended October 31, 2013				Year Ended October 31, 2012
		# of shares		Amount		# of shares		Amount
	Issuance to third parties for services rendered		907,582	$	257,025		—	$	—
	Issuance to third parties for cash		400,000	$	100,000		1,050,000	$	262,500
	Issuance to third parties on exercise of conversion of notes payable		919,847	$	91,882		—	$	—

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Oct. 31, 2013
Earnings Per Share [Abstract]	'
Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share	'
	The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share:
		Years Ended October 31,
		2013		2012
	Weighted-average shares - basic		57,171,924		55,629,034
	Effect of dilutive securities		—		—
	Weighted-average shares - diluted		57,171,924		55,629,034

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Oct. 31, 2013
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'
Aggregate Minimum Annual Lease Commitments Under Non-Cancelable Operating Lease	'
	Aggregate minimum annual lease commitments of the Company under the non-cancelable operating lease as of October 31, 2013 are as follows. (The Company is required in addition to pay a proportionate share of building operational expenses.) :
	Year	Amount
	2014	$	49,639
	2015		49,891
	2016		51,152
	Thereafter		42,627
	Total Minimum Lease Payments	$	193,309

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Tables)	12 Months Ended
	Oct. 31, 2013
Supplemental Cash Flow Information [Abstract]	'
Cash Flow Supplemental Disclosures	'
		For the Year Ended
		October 31,
		2013		2012
	Cash paid during the period for:
	Interest	$	28,116	$	18,221
	Income Taxes		—		—
	Non-cash financing activities:
	Conversion of shareholder loan and accrued expenses to debentures		255,000		—
	Conversion of notes payable including principle, interest and original issue discount		91,882		—
	Value of beneficial conversion feature and warrants issued with debentures issued		746,656		—
	during the year

Nature_of_Business_Details_Nar

Nature of Business (Details Narrative)	1 Months Ended	0 Months Ended
	Jun. 20, 2010	Apr. 23, 2010	Oct. 31, 2013	Jan. 17, 2013	Oct. 31, 2012	Sep. 30, 2009	Apr. 23, 2010	Apr. 23, 2010	Sep. 30, 2009	Jul. 31, 2009
							Minimum [Member]	Maximum [Member]	Maximum [Member]	JAG Media Holdings, Inc [Member]
										Decimal
Adjustment of common stock retrospective exchange ratio in acquisition	'	'	'	'	'	'	'	'	'	20.957
Common stock, shares authorzed	65,000,000	'	150,000,000	150,000,000	150,000,000	500,000,000	65,000,000	150,000,000	650,000,000	'
Reverse stock split	'one-for-ten	'	'	'	'	'	'	'	'	'
		one-for-ten

Basis_of_Presentation_Details_

Basis of Presentation (Details Narrative) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Deficit accumulated during development stage	$44,957,870	$42,039,223

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Schedule of Property Plant and Equipment Depreciated Methods and Rates (Details)	12 Months Ended
	Oct. 31, 2013
Furniture And Fixtures [Member]	'
Property plant and equipment depreciation percentage	20.00%
Property, plant and equipment, depreciation method	'
	declining balance
Lab Equipment [Member]	'
Property plant and equipment depreciation percentage	20.00%
Property, plant and equipment, depreciation method	'
	declining balance
Computer Equipment B Hardware	'
Property plant and equipment depreciation percentage	30.00%
Property, plant and equipment, depreciation method	'
	declining balance
Computer Equipment B Software	'
Property plant and equipment depreciation percentage	50.00%
Property, plant and equipment, depreciation method	'
	declining balance
Leasehold Improvements [Member]	'
Property, plant and equipment, depreciation method	'
	Straight-line over the lesser of the life of the asset or the life of the lease

Property_and_Equipment_Details

Property and Equipment (Details Narrative) (USD $)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation and amortization expense	$14,484	$18,305

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Cost and Accumulated Depreciation and Amortization of Property Plant and Equipment (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Furniture and Fixtures	$12,120	$12,120
Lab Equipment	168,328	168,328
Computer Hardware	19,490	19,490
Computer Software	8,433	8,433
Leasehold Improvements	91,269	91,269
Total Property and Equipment	299,640	299,640
Less Accumulated Depreciation and Amortization	246,297	231,813
Property and Equipment, Net	$53,496	$67,827

Patents_Details_Narrative

Patents (Details Narrative) (USD $)	12 Months Ended		191 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013
Amortization expense	$7,285	$6,882	$26,578
Patents [Member]	'	'	'
Amortization expense	7,285	6,882	'
2014	'	7,300	'
2015	'	7,300	'
2016	'	7,300	'
2017	'	7,300	'
Write-off of net book value of patents	$0	$24,905	'

Patents_Schedule_of_Costs_and_

Patents - Schedule of Costs and Accumulated Amortization of Patents (Details) (USD $)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
CostAndAccumulatedAmortizationLineItems [Line Items]	'	'
Patents, Net	$118,432	$110,031
Patents [Member]	'	'
CostAndAccumulatedAmortizationLineItems [Line Items]	'	'
Patents	144,022	128,336
Less: Accumulated Amortization	-25,590	-18,305
Patents, Net	$118,432	$110,031
Weighted-Average Life	'17 years	'17 years

Due_to_Shareholders_Details_Na

Due to Shareholders (Details Narrative)	12 Months Ended
	Oct. 31, 2013
Due To Shareholders Details Narrative	'
Interest rate of convertible debentures	10.00%

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2013
		CA [Member]	CA [Member]	U S [Member]	U S [Member]	U S [Member]
Operating Loss Carryforwards [Line Items]	'	'	'	'	'	'
Net operating loss carry forwards	'	$9,126,000	$6,319,184	$40,713,000	'	$41,040,000
Operating loss carry forwards expiration period	'	'2014 through 2033	'2014 through 2033	'2020 through 2033	'2020 through 2033	'
Ownership percentage of stock	5.00%	'	'	'	'	'
Increase in ownership percentage of stock	50	'	'	'	'	'

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets Consisted of the Effects of Temporary Differences (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Property and equipment	($18,951)	($14,600)
Net operating loss carryforwards	16,600,883	15,589,530
Unrealized foreign exchange	17,861	16,601
Investment tax credits	402,189	381,836
Transitional tax debits	-25,076	-25,076
Total Deferred Tax Assets	16,976,906	15,948,291
Valuation Allowance	-16,976,906	-15,948,291
Net Deferred Income Taxes	$0	$0

Income_Taxes_Canadian_Combined

Income Taxes - Canadian Combined Statutory Rate to the Company's Effective Tax Rate (Details)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Statutory rate	28.00%	28.00%
Rate differences	0.00%	0.00%
Changes in tax rate	0.00%	-1.10%
Other	0.00%	0.00%
Permanent differences	-5.20%	-18.40%
Change in valuation allowance	-22.80%	-8.50%
Effective tax rate	0.00%	0.00%

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Payables and Accruals [Abstract]	'	'
Accounts Payable	$253,618	$149,258
Income Tax Reserve	220,000	200,000
Research and Development	34,901	70,560
Investor Relations	20,602	21,164
Patent Application Costs	10,430	10,736
Legal Fees	273,731	263,702
Settlement of Lawsuit	199,000	'
Accounting Fees	37,833	70,715
Total	$1,050,115	$786,135

Stock_Based_Compensation_Detai

Stock Based Compensation (Details Narrative) (USD $)	12 Months Ended		191 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013
Stock Based Compensation Details Narrative	'	'	'
Stock-based employee compensation related to stock options	'	'	$192,238
Market price value per share	$0.19	'	$0.19

Stock_Based_Compensation_Summa

Stock Based Compensation - Summary of Common Stock Options Granted, Forfeited or Expired and Exercised Under Plan (Details) (USD $)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Stock Based Compensation - Summary Of Common Stock Options Granted Forfeited Or Expired And Exercised Under Plan Details	'	'
Options, Outstanding beginning balance	30,000	30,000
Options, Granted	'	'
Options, Forfeited/Expired	'	'
Options, Exercised	'	'
Options, Outstanding ending balance	30,000	30,000
Weighted Average Exercise price, Beginning balance	$0.90	$0.90
Weighted Average Exercise price, Granted	'	'
Weighted Average Exercise price, Forfeited/Expired	'	'
Weighted Average Exercise price, Exercised	'	'
Weighted Average Exercise price, Ending balance	$0.90	$0.90

Stock_Based_Compensation_Summa1

Stock Based Compensation - Summarizes Information on Stock Options Outstanding (Details) (USD $)	12 Months Ended
	Oct. 31, 2013
Options Outstanding and Exercisable, Number Outstanding	30,000
Options Outstanding and Exercisable, Weighted Average Remaining Life (Years)	'5 years 9 months
Weighted Average Excercise Price Zero Point Nine Zero [Member]	'
Options Outstanding and Exercisable, Weighted Average Remaining Life (Years)	'5 years 9 months
Weighted Average Excercise Price Zero Point Nine Zero [Member]	'
Options Outstanding and Exercisable, Number Outstanding	30,000
Options Outstanding and Exercisable, Weighted Average Exercise Price	0.9
Options Outstanding and Exercisable, Aggregate Intrinsic Value	0

Stock_Based_Compensation_Fair_

Stock Based Compensation - Fair Value and Received From Exercise Of Stock Option (Details) (USD $)	12 Months Ended		191 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013
Stock Based Compensation - Fair Value And Received From Exercise Of Stock Option Details	'	'	'
Weighted Average Fair Value of Options Granted	'	'	'
Cash Received for Exercise of Stock Options	'	'	$2,781

Capital_Lease_Obligations_Futu

Capital Lease Obligations - Future Minimum Rental Payments Under Capital leases (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Leases, Capital [Abstract]	'	'
Total amount payable in equal monthly installments of $500	'	$3,000
Less: Amount representing interest	'	373
Present value of minimum lease payments	'	2,627
Less: Current portion	'	2,627
Minimum payments balance portion	'	'

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	0 Months Ended	12 Months Ended		191 Months Ended
	Nov. 19, 2012	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013
Notes Payable [Abstract]	'	'	'	'
Line of credit facility, maximum borrowing capacity	$350,000	'	'	'
Line of credit facility, current borrowing capacity	50,000	'	'	'
Line of credit facility original issue discount	50,000	'	'	'
Line of credit facility, interest rate during period	5.00%	'	'	'
Lenders right relating to notes payable description	'	'	'	'
	The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion.
Debt instrument, convertible conversio price	$0.23	$0.25	'	$0.25
Percentage of lowest trading price of debt instrument on before conversion	60.00%	'	'	'
Line of credit facility common stock outstanding percentage	4.99%	'	'	'
Loss (Gain) on Change in Fair Value of Derivative Liability	'	116,663	'	12,537,686
Notes payable amount	'	75,000	'	75,000
Interest and original issue discount	'	$16,882	'	'
Dbet instrument, convertible, conversion into equtiy, number	'	919,847	'	'

Notes_Payable_Summary_of_Notes

Notes Payable - Summary of Notes Payable (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Short-term Debt [Line Items]	'	'
Convertible Note Payable	$75,000	'
Debt Discount b value attributable to conversion feature attached to notes, net of accumulated amortization of $11,983	-48,017	'
Total	11,983	'
Less: Current portion	11,983	'
Total Long-term portion	'	'
Convertible Note Payable, Maturity June 27, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Note Payable	25,000	'
Convertible Note Payable, Maturity September 26, 2014 (Member)	'	'
Short-term Debt [Line Items]	'	'
Convertible Note Payable	$35,000	'

Notes_Payable_Summary_of_Notes1

Notes Payable - Summary of Notes Payable (Details) (Parenthetical) (USD $)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Net of accumulated amortization	11,983	11,983
Convertible Note Payable, Maturity June 27, 2014 [Member]	'	'
Convertible Note Payable, maturity date	27-Jun-14	27-Jun-14
Convertible Note Payable, Maturity September 26, 2014 (Member)	'	'
Convertible Note Payable, maturity date	26-Sep-14	26-Sep-14

Derivative_Liabilities_Details

Derivative Liabilities (Details Narrative) (USD $)	12 Months Ended
	Oct. 31, 2013
DerivativeLiabilitiesLineItems [Line Items]	'
Derivative liabilities	$135,000
Fair value assumptions, exercise price	$0.08
Fair value assumptions, risk free interest rate	0.11%
Fair value assumptions, expected term	'1 year
Fair value assumptions, expected dividend rate	0.00%
Minimum [Member]	'
DerivativeLiabilitiesLineItems [Line Items]	'
Fair value assumptions, exercise price	$0.14
Fair value assumptions, expected term	'7 months 28 days
Fair value assumptions, expected volatility rate	170.00%
Maximum [Member]	'
DerivativeLiabilitiesLineItems [Line Items]	'
Fair value assumptions, exercise price	$0.14
Fair value assumptions, expected term	'10 months 24 days
Fair value assumptions, expected volatility rate	195.00%

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Fair Value of Liabilities Measured on Recurring Basis (Details) (USD $)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Derivative liability on notes payable	$99,702	'
Total decrease in fair value recorded	'	'
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) [Member]	'	'
Derivative liability on notes payable	'	'
Significant Other Observable Inputs (Level 2) [Member]	'	'
Derivative liability on notes payable	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Derivative liability on notes payable	$99,702	'

Fair_Value_Measurements_Schedu1

Fair Value Measurements - Schedule of Fair Value of Estimated Derivative Liabilities Weighted Average Assumption (Details) (USD $)	12 Months Ended
	Oct. 31, 2013
Fair value	$0.08
Expected term (in years)	'1 year
Risk-free interest rate	0.11%
Minimum [Member]	'
Fair value	$0.14
Expected volatility	170.00%
Dividend yield	'
Expected term (in years)	'7 months 28 days
Maximum [Member]	'
Fair value	$0.14
Expected volatility	197.00%
Dividend yield	'
Expected term (in years)	'10 months 24 days

Fair_Value_Measurements_Schedu2

Fair Value Measurements - Schedule of Changes In Fair Value of Financial Liabilities or Derivative Liabilities (Details) (USD $)	12 Months Ended
	Oct. 31, 2013
Fair Value Disclosures [Abstract]	'
Balance at beginning of period	'
Additions to derivative instruments	135,000
Change in fair value of derivative liabilities	116,663
Settlement	-151,961
Balance at end of period	$99,702

Debentures_Payable_Details_Nar

Debentures Payable (Details Narrative) (USD $)

12 Months Ended

191 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Oct. 31, 2013

Oct. 31, 2012

Oct. 31, 2013

Nov. 19, 2012

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Feb. 28, 2013

Feb. 28, 2013

Jun. 30, 2013

31-May-13

Oct. 31, 2013

Minimum [Member]

Maximum [Member]

Warrant [Member]

Series A Convertible Debenture [Member]

Series A Convertible Debenture [Member]

Series B Convertible Debenture [Member]

Series B Convertible Debenture [Member]

Series B Convertible Debenture [Member]

Shareholder [Member]

Director [Member]

Short-term Debt [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Due to shareholders

'

$100,000

$100,000

'

'

'

'

$100,000

$188,584

'

'

'

Debt instrument, interest rate terms

'

'

'

'

'

'

'

10.00%

10.00%

10.00%

10.00%

'

Debt instrument term

'

'

'

'

'

'

'

'3 years

'3 years

'3 years

'3 years

'

Amount of units sold

'

'

'

'

'

'

'

'

'

148,653

500,000

'

Debt instrument, convertible, conversion price

$0.25

'

$0.25

$0.23

'

'

'

$0.25

$0.25

$0.25

$0.25

'

Debt Instrument, Redemption, Description

'

'

'

'

'

'

'

'

'

'

'

'

The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years.

The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years.

Risk-free interest rate

0.11%

'

'

'

'

'

0.18%

'

'

'

'

'

Expected life term

'1 year

'

'

'

'7 months 28 days

'10 months 24 days

'3 years

'

'

'

'

'

Expected dividend rate

0.00%

'

'

'

'

'

0.00%

'

'

'

'

'

Expected volatility rate

'

'

'

'

170.00%

195.00%

'

'

'

'

'

'

Proceeds from warrants

306,900

'

'

'

'

'

'

'

'

'

'

343,996

Increase in additional paid in capital and debt discount

'

'

'

'

'

'

'

'

'

'

'

650,896

Interest expense

$112,609

'

'

'

'

'

'

'

'

'

'

'

Debentures_Payable_Schedule_of

Debentures Payable - Schedule of Debenture Payable (Details) (USD $)	Oct. 31, 2013	Oct. 31, 2012
Short-term Debt [Line Items]	'	'
Debt Discount	($634,047)	'
Total	303,190	'
Less: Current portion	'	'
Total Long-term portion	303,190	'
Series A Convertible Debentures Payable, Maturity at February 27, 2016 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Debentures Payable	288,584	'
Series B Convertible Debentures Payable, Maturity at May 31, 2016 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Debentures Payable	500,000	'
Series B Convertible Debentures Payable, Maturity at June 3, 2016 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Debentures Payable	$148,653	'

Debentures_Payable_Schedule_of1

Debentures Payable - Schedule of Debenture Payable (Details) (Parenthetical)	12 Months Ended
	Oct. 31, 2013
Series A Convertible Debentures Payable, Maturity at February 27, 2016 [Member]	'
Short-term Debt [Line Items]	'
Convertible Debentures Payable, interest rate	10.00%
Convertible Debentures Payable, maturity date	27-Feb-16
Series B Convertible Debentures Payable, Maturity at May 31, 2016 [Member]	'
Short-term Debt [Line Items]	'
Convertible Debentures Payable, interest rate	10.00%
Convertible Debentures Payable, maturity date	31-May-16
Series B Convertible Debentures Payable, Maturity at June 3, 2016 [Member]	'
Short-term Debt [Line Items]	'
Convertible Debentures Payable, interest rate	10.00%
Convertible Debentures Payable, maturity date	3-Jun-16

Deficiency_Details_Narrative

Deficiency (Details Narrative) (USD $)	0 Months Ended			12 Months Ended
	Aug. 31, 2011	Aug. 01, 2009	Jul. 31, 2009	Oct. 31, 2011	Nov. 15, 2013	Sep. 27, 2013
Deficiency Details Narrative	'	'	'	'	'	'
Employees to purchased common stock	75,000	30,000	200,000	275,000	'	'
Stock price, per share	$0.20	$0.90	$3.40	$0.01	$0.25	$0.00

Deficiency_Schedule_of_Warrant

Deficiency - Schedule of Warrants Outstanding (Details)	Oct. 31, 2013	Oct. 31, 2012
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	8,332,500	6,287,085
Issued To Consultant August 1, 2009, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.90 Per Common Share Up To And Including July 31, 2017. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	'	287,085
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	500,000	500,000
Issued To Consultants In September 2011 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including March 20, 2013. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	'	1,500,000
Issued To Consultants In September 2011 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.34 Per Common Share Up To And Including March 20, 2013. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	'	1,500,000
Issued To Consultants In September 2011 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including March 20, 2013. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	'	1,000,000
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.25 Per Common Share Up To And Including February 27, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	600,000	'
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	750,000	'
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	232,500	'
Issued To Consultants August 5, 2013, Entitling The Holders To Purchase 2,500,000 Common Shares In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including August 4, 2023 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	2,500,000	'
Issued To Consultants August 5, 2013, Entitling The Holders To Purchase 1,500,000 Common Shares In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including August 4, 2023 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	1,500,000	'
Issued To Consultant September 3, 2013, Entitling The Holder To Purchase 500,000 Common Shares In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	500,000	'
Issued to shareholder October 29, 2013, entitling the holder to purchase 250,000 common shares in the company at an exercise price of $0.15 per common share up to and including October 29, 2016 [Member}	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	250,000	'

Deficiency_Schedule_of_Warrant1

Deficiency - Schedule of Warrants Outstanding (Details) (Parenthetical) (USD $)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Issued To Consultant August 1, 2009, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.90 Per Common Share Up To And Including July 31, 2017. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	'	1
Warrants, exercise price	'	$0.90
Warrant, last exercisable date	'	31-Jul-17
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.30	$0.30
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.50	$0.50
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.75	$0.75
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$1	$1
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.75	$0.75
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Consultants In September 2011 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including March 20, 2013. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	'	1
Warrants, exercise price	'	$0.10
Warrant, last exercisable date	'	20-Mar-13
Issued To Consultants In September 2011 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.34 Per Common Share Up To And Including March 20, 2013. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	'	1
Warrants, exercise price	'	$0.34
Warrant, last exercisable date	'	20-Mar-13
Issued To Consultants In September 2011 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including March 20, 2013. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	'	1
Warrants, exercise price	'	$0.50
Warrant, last exercisable date	'	20-Mar-13
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.25 Per Common Share Up To And Including February 27, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	'
Warrants, exercise price	$0.25	'
Warrant, last exercisable date	27-Feb-16	'
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	'
Warrants, exercise price	$0.15	'
Warrant, last exercisable date	3-Jun-16	'
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	'
Warrants, exercise price	$0.15	'
Warrant, last exercisable date	3-Jun-16	'
Issued To Consultants August 5, 2013, Entitling The Holders To Purchase 2,500,000 Common Shares In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including August 4, 2023 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	2,500,000	'
Warrants, exercise price	$0.15	'
Warrant, last exercisable date	4-Aug-23	'
Issued To Consultants August 5, 2013, Entitling The Holders To Purchase 1,500,000 Common Shares In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including August 4, 2023 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1,500,000	'
Warrants, exercise price	$0.10	'
Warrant, last exercisable date	4-Aug-23	'
Issued To Consultant September 3, 2013, Entitling The Holder To Purchase 500,000 Common Shares In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	500,000	'
Warrants, exercise price	$0.50	'
Warrant, last exercisable date	31-Jul-18	'
Issued to shareholder October 29, 2013, entitling the holder to purchase 250,000 common shares in the company at an exercise price of $0.15 per common share up to and including October 29, 2016 [Member}	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	250,000	'
Warrants, exercise price	$0.15	'
Warrant, last exercisable date	29-Oct-16	'

Authorized_Share_Capital_Detai

Authorized Share Capital (Details Narrative) (USD $)	1 Months Ended	0 Months Ended
	Jun. 20, 2010	Apr. 23, 2010	Oct. 31, 2013	Jan. 17, 2013	Oct. 31, 2012	Sep. 30, 2009
Common stock, shares authorized	65,000,000	'	150,000,000	150,000,000	150,000,000	500,000,000
Excess stock, shares authorized	'	'	'	'	'	150,000,000
Common stock, par value	$0.00	'	$0.00	'	$0.00	$0.00
Stock authorised after reverse stock split	70,044,000	65,000,000	'	'	'	'
Stockholders' equity, reverse stock split	'one-for-ten	'	'	'	'	'
		one-for-ten
Stock authorised before reverse stock split	700,440,000	'	'	'	'	'
Preferred stock, shares authorized	5,000,000	'	5,000,000	'	5,000,000	'
Series 2 Class B Common Stock [Member]	'	'	'	'	'	'
Series class B common stock shares authorized	40,000	'	'	'	'	'
Series 3 Class B Common Stock [Member]	'	'	'	'	'	'
Series class B common stock shares authorized	4,000	'	'	'	'	'
Maximum [Member]	'	'	'	'	'	'
Common stock, shares authorized	'	150,000,000	'	'	'	650,000,000

Issuance_of_Common_Stock_Sched

Issuance of Common Stock - Schedule of Common Stock Issue (Details) (USD $)	12 Months Ended					191 Months Ended	12 Months Ended
	Oct. 31, 1998	Oct. 31, 2013	Oct. 31, 2010	Oct. 31, 2009	Oct. 31, 2006	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2012
							Third Parties [Member]	Third Parties [Member]
IssuanceOfCommonStockLineItems [Line Items]	'	'	'	'	'	'	'	'
Issuance to third parties for services rendered, shares	'	'	'	'	'	'	907,582	'
Issuance to third parties for services rendered	'	$1,387,025	'	$2,062	$4,305	$4,203,287	$257,025	'
Issuance to third parties for cash, shares	'	'	'	'	'	'	400,000	1,050,000
Issuance to third parties for cash	1	'	77,000	'	'	'	100,000	262,500
Issuance to third parties on exercise of conversion of notes payable, shares	'	919,847	'	'	'	'	919,847	'
Issuance to third parties on exercise of conversion of notes payable	'	'	'	'	'	'	$91,882	'

Redemption_of_Class_B_Common_S1

Redemption of Class B Common Stock (Details Narrative) (USD $)	0 Months Ended
	Feb. 28, 2011
Redemption Of Class B Common Stock	'
Class B Common Stock redemption date	4-Apr-11
Class B Common Stock redemption price, per value	$0.00

Equity_Line_Details_Narrative

Equity Line (Details Narrative) (USD $)	Nov. 15, 2013	Sep. 27, 2013	Oct. 31, 2011	Aug. 31, 2011	Aug. 01, 2009	Jul. 31, 2009
Equity Line	'	'	'	'	'	'
Investor obligated to company due to purchase of company, equity	'	$5,000,000	'	'	'	'
Per share value	$0.25	$0.00	$0.01	$0.20	$0.90	$3.40

Net_Loss_Per_Share_Details_Nar

Net Loss Per Share (Details Narrative)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Earnings Per Share [Abstract]	'	'
Incremental shares excluded from computation of diluted earning per share	12,896,786	6,317,085

Net_Loss_Per_Share_Computation

Net Loss Per Share - Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share (Details)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Earnings Per Share [Abstract]	'	'
Weighted-average shares - basic	57,171,924	55,629,034
Effect of dilutive securities	'	'
Weighted-average shares - diluted	57,171,924	55,629,034

Commitments_and_Contingencies_

Commitments and Contingencies (Details Narrative) (USD $)	1 Months Ended	12 Months Ended
	Apr. 22, 2009	Oct. 31, 2013	Oct. 31, 2012
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Operating leases expense	'	$60,513	$76,602
Former employee related claims	$514,000	'	'

Commitments_and_Contingent_Lia1

Commitments and Contingent Liabilities - Aggregate Minimum Annual Lease Commitments Under Non-Cancelable Operating Lease (Details) (USD $)	Oct. 31, 2013
Commitments And Contingent Liabilities - Aggregate Minimum Annual Lease Commitments Under Non-Cancelable Operating Lease Details	'
2014	$49,639
2015	49,891
2016	51,152
Thereafter	42,627
Total Minimum Lease Payments	$193,309

Supplemental_Disclosure_of_Cas2

Supplemental Disclosure of Cash Flow Information - Cash Flow Supplemental Disclosures (Details) (USD $)	12 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Supplemental Cash Flow Elements [Abstract]	'	'
Cash paid during the period for, Interest	$28,116	$18,221
Cash paid during the period for, Income taxes	'	'
Non-cash financing activities, Conversion of shareholder loan and accrued expenses to debentures	255,000	'
Non-cash financing activities, Conversion of notes payable including principle, interest and original issue discount	91,882	'
Non-cash financing activity, Value of beneficial conversion feature and warrants issued with debentures during the period	$746,656	'

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	0 Months Ended						0 Months Ended
	Nov. 15, 2013	Sep. 27, 2013	Oct. 31, 2011	Aug. 31, 2011	Aug. 01, 2009	Jul. 31, 2009	Jan. 03, 2014
							Subsequent Event [Member]
Common stock issued	200,000	'	'	'	'	'	'
Common stock price, per shares	$0.25	$0.00	$0.01	$0.20	$0.90	$3.40	'
Shares for cash consideration	$50,000	'	'	'	'	'	'
During period shares stock warrants exercised	125,000	'	'	'	'	'	'
Share based compensation arrangement by share based payment award plan pre modification weightage average exercise price	$0.15	'	'	'	'	'	'
Warrants entitled to shareholder to purchase of common stock term	'3 years	'	'	'	'	'	'
Settlement of compensation fo wrongful dismissal	'	'	'	'	'	'	'
							the Company settled a suit from a former employee who claimed compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company for an amount equal to $10,000 plus 700,000 common shares.
Payment of shares paid to former employee under settlement of lawsuit	'	'	'	'	'	'	700,000
Compensation amount	'	'	'	'	'	'	10,000
Settlement of Lawsuit expense	'	'	'	'	'	'	$199,000
Shares exchange to non controlling interest	'	'	'	'	'	'	296,538